

Repatriation Pharmaceutical Benefits Scheme

**Instrument 2013 No. R43**

made under section 91 of the

Veterans' Entitlements Act 1986

**Compilation No. 15**

**Compilation date:** 4 February 2025

**Includes amendments:** F2025L00191

**About this compilation**

**This compilation**

This is a compilation of the *Repatriation Pharmaceutical Benefits Scheme* that shows the text of the law as amended and in force on 4 February 2025 (the ***compilation date***).

The notes at the end of this compilation (the ***endnotes***) include information about amending laws and the amendment history of provisions of the compiled law.

**Uncommenced amendments**

The effect of uncommenced amendments is not shown in the text of the compiled law. Any uncommenced amendments affecting the law are accessible on the Register (www.legislation.gov.au). The details of amendments made up to, but not commenced at, the compilation date are underlined in the endnotes. For more information on any uncommenced amendments, see the Register for the compiled law.

**Application, saving and transitional provisions for provisions and amendments**

If the operation of a provision or amendment of the compiled law is affected by an application, saving or transitional provision that is not included in this compilation, details are included in the endnotes.

**Editorial changes**

For more information about any editorial changes made in this compilation, see the endnotes.

**Modifications**

If the compiled law is modified by another law, the compiled law operates as modified but the modification does not amend the text of the law. Accordingly, this compilation does not show the text of the compiled law as modified. For more information on any modifications, see the Register for the compiled law.

**Self‑repealing provisions**

If a provision of the compiled law has been repealed in accordance with a provision of the law, details are included in the endnotes.

Contents

1A Name of Scheme 1

1C Transitional‑General 1

1D Transitional‑pharmaceutical reimbursement 1

1 Repatriation Pharmaceutical Benefits Scheme 1

2 Purpose of the Repatriation Pharmaceutical Benefits Scheme 1

Part 1—Interpretation 2

3 Definitions 2

4 Notification of certain matters in the Explanatory Notes 9

5 Department to notify of certain matters as agent of the Commission 9

Part 2—Prescribing of Benefits Procedure by Medical Practitioners 10

6 Prior Approval 10

7 Restrictions 10

8 Prescribing provisions 11

9 Application of PBS Schedule restrictions and RPBS Schedule restrictions 11

10 Prescriptions to conform with State or Territory Law 11

11 Form of prescriptions 11

11AA Writing prescriptions‑general 12

11A Writing of prescriptions‑prescriptions other than medication chart prescriptions 12

11B Writing prescriptions — medication chart prescriptions 14

11C Writing prescriptions—additional requirements for all electronic prescriptions 18

11D Writing prescriptions—additional information that may be included in electronic prescriptions 18

12 When prescriptions are invalid 18

13 Maximum quantity and repeats allowed 19

14 Prescribing outside the RPBS Schedule or PBS Schedule 19

15 Medical Practitioner subject to this Scheme 19

Part 3—Supply of Pharmaceutical Benefits 20

16 Supply of Pharmaceutical Benefits — Procedure by Community Pharmacists 20

16AAA Pharmaceutical benefits supplied under a special arrangement 20

16AA Supply of pharmaceutical benefit on basis of medication chart prescription 22

 Continued Dispensing 24

16A When Pharmaceutical benefits may be supplied by Community Pharmacists without prescription 24

16AB Information about status of person—continued dispensing and medication chart prescriptions 27

17 Substitution of lesser priced alternative brand of drug 27

18 Community Pharmacist to be satisfied as to entitlement 28

19 Dispensing of deleted items 28

20 Use of forms as notified by the Department or the Commission 28

21 Financial responsibility 28

21A Dispensed Price for RPBS Schedule Pharmaceutical benefits 29

22 Refund in certain circumstances 29

23 Expenses incurred in obtaining Pharmaceutical Benefits while not in receipt of a pharmaceutical allowance 30

Part 4—Claims by Community Pharmacists 31

24 Lodgement of Claims by Community Pharmacists 31

25 Claims Requirements and Payment 31

Part 5—Payments to Community Pharmacists 32

26 Payment of Dispensed Price 32

30 Fees not payable in some circumstances 32

31 Community Pharmacist not entitled to demand or receive payments 32

32 Community Pharmacist to issue receipt where certain payments received 32

32A Additional community supply support payment 32

Part 5A—Pharmaceutical Reimbursement 35

Definitions: 35

33 35

34 35

35 35

36 Eligibility for Payment of Pharmaceutical Reimbursement 35

37 Calculation of annual value of pharmaceutical allowance component of Pension Supplement, Veterans Supplement, MRCA supplement 36

38 Payment of Pharmaceutical Reimbursement 37

38A Five Year Limit on Payment of Pharmaceutical Reimbursement 37

39 Pharmaceutical Reimbursement Calculator 38

40 Uncounted Co‑Payment 38

Part 5B—Under Co‑payment Data Collection 39

40A Giving information 39

Part 6—Miscellaneous 40

41 Standards 40

45 Keeping documents‑other than for continued dispensing or medication chart prescriptions 40

45A Keeping documents—continued dispensing 41

45B Keeping documents—medication chart prescriptions 41

46 Agreement with the Pharmacy Guild of Australia 42

47 Transitional provision relating to the Veterans’ Affairs Pharmaceutical Benefits Schemes (Electronic Prescriptions and Active Ingredient Prescribing) Amendment Instrument 2019 42

SCHEDULE 1 — INCORPORATED DOCUMENTS 43

Schedule 2—Pharmaceutical benefits not covered by PBS—continued dispensing 44

Endnotes 62

Endnote 1—About the endnotes 62

Endnote 2—Abbreviation key 63

Endnote 3—Legislation history 64

Endnote 4—Amendment history 65

1A Name of Scheme

 This instrument is the *Repatriation Pharmaceutical Benefits Scheme*.

1C Transitional‑General

 Any process under the *revoked scheme* that had not been finalised before the commencement of this *Scheme* is to be completed under this *Scheme* as if it had commenced under this *Scheme*.

1D Transitional‑pharmaceutical reimbursement

For thepurpose of working out a *pharmaceutical reimbursement*, a co‑payment by an *Eligible Person* for a *Pharmaceutical benefit* under the *revoked scheme*, that could have ***been*** counted for a pharmaceutical reimbursement under the *revoked Scheme* but in respect of which a pharmaceutical reimbursement had not been made immediately before the commencement of this Scheme, is taken to be a *co‑payment* for a *Pharmaceutical benefit* under this *Scheme*.

1 Repatriation Pharmaceutical Benefits Scheme

The Repatriation Pharmaceutical Benefits Scheme is authorised by, and subject to, section 91 of the *Veterans’ Entitlements Act 1986*.

2 Purpose of the Repatriation Pharmaceutical Benefits Scheme

The Repatriation Pharmaceutical Benefits Scheme enables *Community Pharmacists* to supply *Pharmaceutical benefits* to *Eligible Persons*.

Part 1—Interpretation

3 Definitions

 For the purposes of this Scheme, unless a contrary intention appears:

***accepted disability*** means a war‑caused injury or a war‑caused disease, a defence‑caused injury or a defence‑caused disease or a *DRCA disability*.

Note: war‑caused injury etc is defined in the *Act*.

***Act*** means the *Veterans’ Entitlements Act 1986*.

***approval number*** means a number allotted by the *Secretary* or the *Minister for Health* under section 16 of the *National Health (Pharmaceutical Benefits) Regulations 2017* to an approval under the *National Health Act 1953* of a person described in the section who, under the Scheme, is a *Community Pharmacist*.

***approved hospital*** means a hospital in respect of which the hospital authority is approved under section 94 of the *National Health Act 1953*.

***Approved Hospital Authority*** has the meaning given by subsection 84(1) of the *National Health Act 1953*.

***approved information technology requirements*** means information technology requirements of a kind approved in writing by the *Secretary* under section 12 of the *National Health (Pharmaceutical Benefits) Regulations 2017* for the purposes of the provision in those regulations in which the expression is used.

***Approved Medical Practitioner*** means a medical practitioner approved under section 92 of the *National Health Act 1953* for the purposes of supplying *Pharmaceutical benefits*.

***approved supplier*** has the meaning given in Part VII of the *National Health Act 1953*.

***Authorised Midwife*** has the meaning given by subsection 84(1) of the *National Health Act 1953*.

***Authorised Nurse Practitioner*** has the meaning given by subsection 84(1) of the *National Health Act 1953*.

***authority prescription*** means a prescription of a *Pharmaceutical benefit* for which *Prior Approval* under section 6 is required.

***Authority Prescription Form*** means a *prescription* in the form, if any, for an “authority prescription” under the *National Health (Pharmaceutical Benefits) Regulations 2017*.

***Chief Executive Medicar*e** has the meaning given by the*Human Services (Medicare) Act 1973*.

***claims rules*** mean the rules, in force from time to time, made under subsections 98AC(4) and 99AAA(8) of the *National Health Act 1953*.

***Commission*** means the Repatriation Commission continued in existence by section 179 of the *Veterans’ Entitlements Act 1986*.

***Community Pharmacist*** means:

 (a) a registered pharmacist approved for the purposes of section 90 of the *National Health Act 1953* in charge of a community pharmacy; or

 (b) a registered pharmacist approved for the purposes of section 90 of the *National Health Act 1953*, being the manager of a registered Friendly Society Dispensary; or

 (c) an Approved Hospital Authority; or

 (d) an Approved Medical Practitioner.

***concessional beneficiary*** has the same meaning it has in section 84 of the *National Health Act 1953*, in force from time to time.

***concessional beneficiary safety net*** has the same meaning it has in section 99F of the *National Health Act 1953*, in force from time to time.

***concession card*** has the meaning given by subsection 84(1) of the *National Health Act 1953*.

***continued dispensing supply*** means the supply of *Pharmaceutical benefits* in the circumstances in paragraph 16A.

***co‑payment***, in respect of a *Pharmaceutical benefit*, means that part of the price of a *Pharmaceutical benefit* that is borne by the *Eligible Person* in relation to a *Pharmaceutical benefit* made available under the *Scheme*.

***deferred supply authorisation*** means the situation described in section 53 of the *National Health (Pharmaceutical Benefits) Regulations 2017*.

Note: generally a deferred supply authorisation occurs where a prescription contains a direction to supply more than 1 *Pharmaceutical benefit* and the *Community Pharmacist* to whom the *prescription* is presented, at the request of the person for whom the prescription is written, defers the supply of one or more of the *Pharmaceutical benefits*.

***Department*** means the Department of Veterans’ Affairs.

***dependant***, in relation to a *concessional beneficiary*, has the meaning given by Part VII of the *National Health Act 1953*.

***dispensed price*** means:

 (a) for a *Pharmaceutical benefit* included in the *PBS* and supplied under the *Scheme* — the dispensed price for the *Pharmaceutical benefit* in the *PBS*;

Note: the dispensed price in the *PBS* is described as “Dispensed Price for Max.Qty”

 (b) for a *Pharmaceutical benefit* included in the *RPBS Schedule* and supplied under the *Scheme* — the dispensed price for the *Pharmaceutical benefit* in the *RPBS Schedule*;

Note: the dispensed price in the *RPBS Schedule* is described as “Dispensed Price for Max.Qty”

 (c) for a *Pharmaceutical benefit* not included in the *PBS* or the *RPBS Schedule* and supplied under the *Scheme* — the dispensed price for the *Pharmaceutical benefit* worked out under the *RPBS Schedule*.

Note: see the information in the *RPBS Schedule* under the headings: “Pricing of Non‑Schedule Ready Prepared Items” and “Pricing of Non‑Schedule Extemporaneously Prepared Items”.

***DRCA disability*** means an injury (within the meaning of the *Safety, Rehabilitation and Compensation (Defence‑related Claims) Act 1988*):

(a) for which the Military Rehabilitation and Compensation Commission has accepted liability to pay compensation under that Act; and

(b) for which the person with the injury is eligible to be provided with treatment under Part V of the *Act*.

Note 1: In the *Safety, Rehabilitation and Compensation (Defence‑related Claims) Act 1988* the definition of *injury* includes a disease (see section 5A of that Act).

Note 2: Section 85(2A) of the *Act* provides eligibility for treatment of a person with an injury under the *Safety, Rehabilitation and Compensation (Defence‑related Claims) Act 1988*.

***Drugs*** or ***Medicines*** means ***goods for therapeutic use*** as defined for human use by the *Therapeutic Goods Act 1989*.

***Eighth Community Pharmacy Agreement*** means the written agreement of that name between the Commonwealth and The Pharmacy Guild of Australia about the delivery of PBS medicines and related services, as in force from time to time.

***electronic medication chart*** has the meaning given by subsection 11B(8).

***electronic prescription*** means a prescription that is prepared and submitted:

 (a) in accordance with *approved information technology requirements* (if any), by means of an *eligible electronic communication*; and

 (b) in accordance with the appropriate form approved by the *Secretary* under:

 (i) subparagraph 40(2)(c)(ii) (prescriptions other than medication chart prescriptions) of the *National Health (Pharmaceutical Benefits) Regulations 2017*; or

 (ii) subsection 41(5) (medication chart prescriptions) of the *National Health (Pharmaceutical Benefits) Regulations 2017*.

***eligible electronic communication*** means:

 (a) an electronic communication of a kind approved by the Secretary under section 11 of the *National Health (Pharmaceutical Benefits) Regulations 2017* for the purposes of the provision in which the expression is used; or

 (b) if no such approval is in force for the purposes of the provision in which the expression is used—any electronic communication.

***Eligible Person*** means:

 (a) a person who holds a Repatriation Health Card ‑ For All Conditions; or

 (b) a person who holds a Repatriation Health Card ‑ For Specific Conditions; or

 (c) a person who holds a Repatriation Pharmaceutical Benefits Card.

***entitlement card*** has the meaning given by subsection 84(1) of the *National Health Act 1953*.

***Explanatory Notes*** means:

(a) the document forming part of the Pharmaceutical Benefits Scheme that is SECTION 1‑ EXPLANATORY NOTES; and

(b) the document forming part of the Pharmaceutical Benefits Scheme that is the RPBS Explanatory Notes;

being the version of the documents in the form in which they exist from time to time.

***general patient safety net*** has the same meaning it has in section 99Fof the*National Health Act 1953*, in force from time to time.

***healthcare identifier*** has the same meaning as in the *Healthcare Identifiers Act 2010*.

***healthcare provider organisation*** has the same meaning as in the *Healthcare Identifiers Act 2010*.

***income support payment*** is a service pension (defined in subsection 5Q(1) of the *Act* or an income support supplement (referred to in Part IIIA of the *Act*).

***income support payment under the Social Security Act 1991*** meansa payment referred to in the definition of “income support payment” in subsection 23(1) of the *Social Security Act 1991*.

***Medical Practitioner*** has the same meaning as “medical practitioner” has in the *Health Insurance Act 1973*.

***medicare number*** has the meaning given by subsection 84(1) of the *National Health Act 1953*.

***medication chart*** has the meaning given by subsection 11B(6).

***medication chart prescription*** has the meaning given by section 11B.

***Minister for Health*** means the Minister administering the *National Health Act 1953*.

***MRCA supplement*** means a payment under section 300 of the *Military Rehabilitation and Compensation Act 2004*.

***paper‑based prescription*** means a prescription that is prepared in duplicate in accordance with subsection 40(2) of the *National Health (Pharmaceutical Benefits) Regulations 2017*.

***PBS or Pharmaceutical Benefits Scheme*** means the document entitled “SCHEDULE OF PHARMACEUTICAL BENEFITS” with International Standard Serial Number 1037‑3667, being the version of the document in the form in which it exists from time to time.

***PBS prescriber*** has the meaning given by subsection 84(1) of the *National Health Act 1953*.

***PBS prescriber number*** means the number given by the *Chief Executive Medicare* to a person who may prescribe a pharmaceutical benefit under the *National Health Act 1953*.

***PBS Schedule*** means the collection of instruments made under Part VII of the *National Health Act 1953* (the Act) by the Minister who administers that Act, as those instruments are in force from time to time.

***pension supplement*** has the same meaning it has in subsection 5Q(1) of the *Act*, in force from time to time.

***pharmaceutical allowance*** means the component of the *veterans supplement* or *pension supplement* or *MRCA supplement* or*war widow/war widower pension* that is to assist with the purchase of *Pharmaceutical benefits*, the calculated value of which isreferred to in paragraph 37 (pharmaceutical allowance component) of Part 5A.

***pharmaceutical benefit has a drug*** has the same meaning as in Part VII of the *National Health Act 1953*.

***Pharmaceutical benefits*** has the same meaning as “pharmaceutical benefits” in subsection 91(9) of the *Veterans’ Entitlements Act 1986*.

***pharmaceutical item*** has the meaning given in Part VII of the *National Health Act 1953*.

***pharmaceutical reimbursement*** means the financial amount described in paragraphs 33‑35 of Part 5A.

***Prior Approval*** means the prior approval of the *Commission*.

***relevant streamlined authority code***, for a pharmaceutical benefit that is prescribed, means the streamlined authority code that is part of:

 (a) the circumstances determined under paragraph 85(7)(b) of the *National Health Act 1953* for the *Pharmaceutical benefit*; or

 (b) the conditions determined under subsection 85A(2A) of the *National Health Act 1953* for the *Pharmaceutical benefit*.

***Repatriation Health Card ‑ For All Conditions*** means an identification card, or written authorisation, provided to:

 (a) a person eligible under section 85 of the *Veterans’ Entitlements Act 1986* for treatment, subject to the *Treatment Principles*, for all injuries or diseases; or

 (b) a person eligible under section 86 of the *Veterans’ Entitlements Act 1986* for treatment, subject to the *Treatment Principles*, for all injuries or diseases.

***Repatriation Health Card ‑ For Specific Conditions*** means an identification card, or written authorisation, provided to a person who is eligible:

 (a) under section 85 of the *Veterans’ Entitlements Act 1986* for treatment, for war‑caused or defence‑caused injuries or diseases, and certain specified conditions; or

 (b) for treatment under a determination made under section 88A of the *Veterans’ Entitlements Act 1986*.

***Repatriation Pharmaceutical Benefits Card*** means an identification card entitled 'Repatriation Pharmaceutical Benefits Card' which is provided to a person pursuant to section 93X of the *Veterans' Entitlements Act 1986* and which entitles the person to pharmaceutical benefits in accordance with this Scheme.

Note: Part VA of the Veterans' Entitlements Act 1986 (Act) has the effect of deeming an eligible Commonwealth veteran, an eligible allied veteran, and an eligible allied mariner, to be entitled to pharmaceutical benefits under the *Repatriation Pharmaceutical Benefits Scheme* as if such person was eligible for treatment comprised of pharmaceutical benefits under Part V of the Act.

***Repatriation Schedule of Pharmaceutical Benefits*** means all of the content in the *Pharmaceutical Benefits Scheme* for the part with the heading “Repatriation Pharmaceutical Benefits Scheme”.

***repeat authorisation form*** means the form mentioned in subparagraph 52(3)(a)(i) of the *National Health (Pharmaceutical Benefits) Regulations 2017*.

***residential care*** has the meaning given by section 41–3 of the *Aged Care Act 1997*.

***residential care service*** has the meaning given by the *Aged Care Act 1997*.

***revoked scheme***means the *Repatriation Pharmaceutical Benefits Scheme* (1995 No.12).

***RPBS*** means the Repatriation Pharmaceutical Benefits Scheme.

***RPBS Explanatory Notes*** means the document forming part of the *Pharmaceutical Benefits Scheme* that is the RPBS Explanatory Notes being the version of the document in the form in which it exists from time to time.

***RPBS prescriber*** means an *Approved Medical Practitioner*, an *Authorised Midwife* or an *Authorised Nurse Practitioner*.

Note: an RPBS prescriber who is an *Authorised Midwife* or an *Authorised Nurse Practitioner* may only prescribe a *Pharmaceutical benefit* listed on the *PBS* and a prescription by an *Authorised Midwife* or an *Authorised Nurse Practitioner* for a *Pharmaceutical benefit* that is not available on the *PBS* is not recognised under the *Scheme*, even if the *Pharmaceutical benefit* is available under the *Scheme* on the prescription of, say, an *Approved Medical Practitioner*.

***RPBS Schedule*** means the document forming part of the *Pharmaceutical Benefits Scheme* that is the *Repatriation Schedule of Pharmaceutical Benefits*, being the version of the document in the form in which it exists from time to time.

***safety net***, in respect of its application to a person under this *Scheme*, means the *concessional beneficiary safety net* or *general patient safety net*, whichever amount first applies to the person for the purposes of section 84C of the*National Health Act 1953*, in force from time to time.

Note: under section 84C of the *National Health Act 1953* a concession card or entitlement card is issued when a person reaches their Safety Net. The card is issued for the “relevant entitlement period”. The relevant entitlement period is the remainder of the calendar year after the card is issued.

***Scheduled item*** means an item in the *PBS Schedule* or the *RPBS Schedule*.

***Scheme*** means the *Repatriation Pharmaceutical Benefits Scheme*.

***Secretary*** has the meaning given in Part 1 of the *National Health Act 1953*.

***social security pension supplement*** means a rate or amount worked out under section 20A of the *Social Security Act 1991*.

 ***special arrangement*** means the *National Health (COVID‑19 Supply of Pharmaceutical Benefits) Special Arrangement 2020*(the instrument)made by the *Minister for Health* under section 100 of the *National Health Act 1953* to modify thearrangements for the supply of *Pharmaceutical benefits* under Part VII of that Act.

***Standard Prescription Form*** means a *prescription* prepared in accordance with subsection 40(2) of the *National Health (Pharmaceutical Benefits) Regulations 2017*.

Note: a Standard Prescription Form does not include a *medication chart prescription*.

***supply certification form*** means the form of that name in the *claims rules*.

***Treatment Principles*** is the written document prepared by the Repatriation Commission, approved by the Minister under section 90 of the *Veterans’ Entitlements Act 1986*, and in force from time to time.

***veterans supplement***means the payment under section 118A of the *Act*.

***war‑caused or defence‑caused injuries or diseases***means the injuries or diseases described in, respectively, section 9 and 70 of the *Act*; and in relation to a person with a *DRCA disability* means the person’s injury (within the meaning of the *Safety, Rehabilitation and Compensation (Defence‑related Claims) Act 1988*) was caused by, or arose out of, the person’s employment in the Defence Force that is covered by the *Safety, Rehabilitation and Compensation (Defence‑related Claims) Act 1988*.

***war widow/war widower pension*** means a payment received by awar widow/war widower —pensioner comprised of:

 (a) a pension under Part II or IV of the Act at a rate determined under or by reference to subsection 30(1) of the *Act*; or

 (b) a lump sum mentioned in paragraph 234(1)(b) of the MRCA or a weekly amount mentioned in that paragraph.

Note: MRCA is defined in subsection 5Q(1) of the *Act* as the *Military Rehabilitation and Compensation Act 2004*.

Note: references in the *Scheme* to paragraphs, subparagraphs, sections and subsections are interchangeable. For example a reference to “paragraph 10” of the Scheme is the same as a reference to “section 10” of the Scheme and vice versa.

4 Notification of certain matters in the Explanatory Notes

 Where it is provided for the *Department* or the *Commission* to notify of certain matters under the *Scheme*, the inclusion of the matter in the *RPBS Explanatory Notes* and publication of the *RPBS Explanatory Notes* (as part of the publication of the *Pharmaceutical Benefits Scheme* which includes the *RPBS Explanatory Notes*) shall be taken to constitute such notification.

5 Department to notify of certain matters as agent of the Commission

3B. Where it is provided that the *Department* may notify of certain matters, the *Department* may only do so for and on behalf of the *Commission*, as its agent.

Part 2—Prescribing of Benefits Procedure by Medical Practitioners

6 Prior Approval

 (a) The *Commission* may approve any matters requiring **“Prior Approval”**; and

 (b) *Prior Approval* must be sought, in advance, in accordance with an *Authority Prescription Form*.

7 Restrictions

 Restrictions apply to the prescribing of certain items. These include:

 (a) **items — quantities and repeats:** those listed in the *RPBS Schedule* or *PBS Schedule*;

 (b) **surgical appliances and other treatment aids:** surgical appliances and other treatment aids provided under the *Treatment Principles* may not be prescribed unless specifically listed in the *RPBS Schedule*;

 (c) **admixtures:** the following restrictions apply to admixtures:

 (i) admixture of two or more ready‑prepared items into a single combined form, or the addition of one or more supplementary ingredients to a ready‑prepared item, is not recognised as a *Pharmaceutical benefit*;

 (ii) the extemporaneous prescribing of two or more official formulary preparations in a single combined form, or the addition of one or more supplementary ingredients to an official formulary preparation, is a recognised *Pharmaceutical benefit*; and

 (iii) where one or more of the components of a preparation specified in subsubparagraph (ii) are non‑*RPBS Schedule* or non‑*PBS Schedule* items, Prior Approval is required for their prescribing;

 (d) **conformity with standards:** no drug or therapeutic substance shall be prescribed unless it conforms with the specific or general standards as determined by the relevant Minister under the *Therapeutic Goods Act 1989.*

 (e) **basis for prescribing:** the prescribing of therapeutic substances other than on the clinical diagnosis of a *Medical Practitioner*, *Authorised Nurse Practitioner* or *Authorised Midwife* shall be invalid;

Note: an RPBS prescriber who is an *Authorised Midwife* or an *Authorised Nurse Practitioner* may only prescribe a *Pharmaceutical benefit* listed on the *PBS* and a prescription by an *Authorised Midwife* or an *Authorised Nurse Practitioner* for a *Pharmaceutical benefit* that is not available on the *PBS* is not recognised under the *Scheme*, even if the *Pharmaceutical benefit* is available under the *Scheme* on the prescription of, say, an *Approved Medical Practitioner*.

 (f) **approval for therapeutic use:** it is invalid to prescribe:

 (i) an item that is not approved for therapeutic use in the treatment of human illness by the relevant Commonwealth, State or Territory Government agencies, or

 (ii) an item for use if it is not in accordance with the terms and conditions specified by the relevant Government agencies in approving the item as a therapeutic substance;

 (g) **Prior Approval for non‑conforming items:** any drug or medicine intended for use other than in conformity with the requirements in subparagraph (d) requires *Prior Approval*;

 (h) **PBS Schedule restricted items:** the prescribing of *PBS Schedule* restricted items is to comply with the restrictions relating to the prescribing of such items as indicated in the *PBS Schedule* unless *Prior Approval* is obtained to prescribe otherwise;

 (j) **RPBS Schedule restricted items:** the prescribing of *RPBS Schedule* restricted items under this Part is to comply with the restrictions relating to the prescribing of such items as indicated in the *RPBS Schedule* unless *Prior Approval* is obtained to prescribe otherwise;

 (k) **Prior Approval for non‑Schedule items:** the prescribing of an item not included in the *RPBS Schedule* or *PBS Schedule* requires *Prior Approval.*

8 Prescribing provisions

7.The *PBS Schedule* and *RPBS Schedule* are the primary references for the prescribing of *Pharmaceutical benefits*.

9 Application of PBS Schedule restrictions and RPBS Schedule restrictions

8.Restrictions specified in the *PBS Schedule* and *RPBS Schedule* which limit supply of items to a particular class of person, or are reserved for specified purposes or require an authority to prescribe, apply unless *Prior Approval* is obtained to prescribe otherwise.

10 Prescriptions to conform with State or Territory Law

9. For a *prescription* to be recognised by the Commission it must conform with the provisions of State or Territory law.

11 Form of prescriptions

10. Who can write Prescriptions

 (1) Prescriptions are to be written by a *Medical Practitioner*, *Authorised Nurse Practitioner* or *Authorised Midwife* and except where inconsistent with the *Scheme* are to:

 (a) satisfy the requirements for prescriptions in the *National Health (Pharmaceutical Benefits) Regulations 2017*; and

 (b) in the case of a prescription written by an *Authorised Nurse Practitioner* or *Authorised Midwife* — only be for a *Pharmaceutical benefit* the person is permitted to prescribe under the *National Health Act 1953* (including under the instruments under that Act).

Note: an RPBS prescriber who is an Authorised Midwife or an Authorised Nurse Practitioner may only prescribe a Pharmaceutical benefit listed on the PBS and a prescription by an Authorised Midwife or an Authorised Nurse Practitioner for a Pharmaceutical benefit that is not available on the PBS is not recognised under the Scheme, even if the Pharmaceutical benefit is available under the Scheme on the prescription of, say, an Approved Medical Practitioner.

11AA Writing prescriptions‑general

 A prescription for the supply of a *Pharmaceutical benefit* must be written in accordance with;

 (a) either:

 (i) section 11A (prescriptions other than medication chart prescriptions); or

 (ii) section 11B (medication chart prescriptions); and

 (b) if the prescription is an electronic prescription—section 11C (additional requirements for all electronic prescriptions).

Note: other provisions of the *Scheme* may also contain requirements for writing of prescriptions.

11A Writing of prescriptions‑prescriptions other than medication chart prescriptions

 (1) An *RPBS prescriber* writes a prescription in accordance with this *Scheme* if the *RPBS prescriber* :

 (a) prepares the prescription:

 (i) in duplicate, by handwriting the prescription in ink on a prescription form:

 (A) that is as nearly as practicable 18 centimetres long by 12 centimetres wide; and

 (B) on which appears the name and address of the *RPBS prescriber* and, subject to subsection (4), the letters ‘RPBS’(or ‘DVA’); and

 (C) on the original of which appear the words ‘pharmacist/patient copy’; and

 (D) on the duplicate of which appear the words ‘Medicare Australia/DVA copy’; or

 (ii) in duplicate, by means of a computer on a prescription form:

 (A) that is as nearly as practicable 18 centimetres long by 12 centimetres wide; and

 (B) on which appears the name and address of the *RPBS prescriber* and, subject to subsection (4), the letters ‘RPBS’ (or ‘DVA’); and

 (C) on the original of which appear the words ‘pharmacist/patient copy’; and

 (D) on the duplicate of which appear the words ‘Medicare Australia/DVA copy’; and

 (E) that is approved in writing for the purpose by the Secretary (as defined in the *National Health Act 1953*); or

 (iia) by means of a form:

 (A) on which appear the name and address of the *RPBS prescriber* and the letters ‘RPBS’ (or ‘DVA’); and

 (B) that is approved in writing by the Secretary (as defined in the *National Health Act 1953*) for the purpose of writing an electronic prescription; or

 (iii) by another method approved in writing by the Secretary (as defined in the *National Health Act 1953*); and

 (b) signs the prescription after it is prepared; and

 (c) for an *authority prescription*—writes on it that *prior approval* has been obtained (if the case); and

 (d) specifies on the prescription the date on which the prescription is written; and

 (e) for a *Authorised Midwife* or *Authorised Nurse Practitioner*—states in the prescription the number allotted to his or her approval under section 16 of the *National Health (Pharmaceutical Benefits) Regulations 2017*; and

 (f) states in the prescription the name of the person for whom the *Pharmaceutical benefit* is prescribed and the address of that person; and

 (g) identifies in the prescription the *Pharmaceutical benefit* in accordance with subsection (1A); and

 (h) states in the prescription:

 (i) the quantity or number of units of the *Pharmaceutical benefit* to be supplied; and

 (ii) if the supply of the benefit is to be repeated—the number of times it is to be repeated; and

 (i) if the *Pharmaceutical benefit* to be supplied is not a ready‑prepared pharmaceutical benefit(as defined in the *National Health (Pharmaceutical Benefits) Regulations 2017*)—indicates in the prescription the manner in which the *Pharmaceutical benefit* is to be administered.

 (1A) For the purposes of paragraph (1)(g), the *RPBS prescriber* must identify in the prescription:

 (a) if:

 (i) the prescription is prepared in accordance with paragraph (1)(a); or

 (ii) the prescription is for the supply of a *Pharmaceutical benefit* that has 4 or more drugs; or

 (iii) the prescription is for the supply of a *Pharmaceutical benefit* that is specified by the Secretary, in writing, for the purposes of subparagraph 40(2A)(a)(iii) of the *National Health (Pharmaceutical Benefits) Regulations 2017;* or

 (iv) the prescription is for the supply of a *Pharmaceutical benefit* listed under the heading “Various” in the *RPBS Schedule*;

 the *Pharmaceutical benefit* by such particulars as are necessary to identify the *Pharmaceutical benefit*; or

 (b) otherwise:

 (i) each drug that the *Pharmaceutical benefit* has; and

 (ii) if the *RPBS prescriber* considers that it is necessary for the medical treatment of the person for whom the *Pharmaceutical benefit* is to be supplied to identify a brand of the pharmaceutical item that the *Pharmaceutical benefit* has—the brand of the pharmaceutical item.

 (1B) If subparagraph (1A)(b)(ii) applies, the brand of the pharmaceutical item must be listed after the drugs that the *Pharmaceutical benefit* has.

 (1C) Subsection (1A) does not apply to the extent that it would be contrary to a law of a State or Territory that would otherwise apply.

 (2) A prescription written in accordance with this section must not provide for the supply of a *Pharmaceutical benefit* to:

 (a) a person if the *RPBS prescriber* has written, on the same day, another prescription for the supply of the same or an equivalent *Pharmaceutical benefit* to the person; or

 (b) more than 1 person.

 (3) For the purposes of paragraphs (2)(b), (c) and (d), a prescription must not be prepared using a computer program that:

 (a) operates, or may operate, to indicate on a prescription by default, for the purposes of subsection 103(2A) of the *National Health Act 1953*, that only the brand of pharmaceutical benefit specified in the prescription is to be supplied; or

 (b) if paragraph (2A)(b) of this section applies to the prescription—operates, or may operate, to indicate on a prescription by default a brand of the pharmaceutical item that the pharmaceutical benefit has.

11B Writing prescriptions — medication chart prescriptions

Writing prescription by completing section of medication chart

 (1) An *RPBS prescriber* writes a prescription (***a medication chart prescription***) for a *Pharmaceutical benefit* in accordance with this section if:

 (a) the person for whom the *Pharmaceutical benefit* is prescribed is receiving treatment in or at:

 (i) a *residential care service* at which the person is receiving *residential care*; or

 (ii) an *approved hospital;* and

 (b) the *RPBS prescriber* completes a section of a *medication chart* for the person in relation to the *Pharmaceutical benefit* in accordance with

 (i) subsection (3) and

 (ii) if the *prescription* would be an *authority prescription* other than an *authority prescription* referred to in subsection (4A) – subsection (4).

 (2) A reference in the *Scheme* to a *prescription*, or a *medication chart prescription*, includes a reference to the completed section of the chart by which a *medication chart prescription* was written.

Completing section of medication chart—general

 (3) An *RPBS prescriber* completes a section of a *medication chart* in accordance with this subsection for a person (the ***patient***) in relation to a *Pharmaceutical benefit* if:

 (a) the *RPBS prescriber* writes in the section of the chart:

 (i) particulars to identify the *Pharmaceutical benefit* in accordance with subsection (3A); and

 (ii) the date on which the *Pharmaceutical benefit* is prescribed; and

 (iii) the *Pharmaceutical benefit’s* dose, frequency of administration and route of administration; and

 (iv) the letters ‘RPBS’ or ‘DVA’; and

 (b) the chart contains the following information:

 (i) the *RPBS prescriber’s* full name, address and *PBS prescriber number* (if a *PBS prescriber*);

 (ii) the patient’s full name;

 (iii) the patient’s medicare number;

 (iv) the number of any *entitlement card* or *concession card* held by the patient;

 (v) if the patient is a *concessional beneficiary* or the dependant of a *concessional beneficiary* – the number of any card issued by the Commonwealth and held by the *concessional beneficiary* that is evidence that the patient is entitled to receive the *Pharmaceutical benefit* on terms appropriate for the supply of the benefit to a patient of that kind;

 (vi) the name of the *residential care service* or *approved hospital* in or at which the patient is receiving treatment;

 (vii) if the patient is receiving treatment in or at a *residential care service*—the Residential Aged Care Service ID for the *residential care service*;

 (viii) if the patient is receiving treatment in or at an *approved hospital*—the patient’s address and;

 (c) the *RPBS prescriber* writes his or her signature:

 (i) in the section of the chart; and

 (ii) except in the case of an *electronic prescription*—on the cover page of the chart; and

 (d) the section of the chart does not provide for the supply of a *Pharmaceutical benefit* to more than one person; and

 (e) the section of the chart is not completed using a computer program that operates, or may operate, to indicate on a prescription by default, for subsection 103(2A) of the *National Health Act 1953*, that only the brand of *Pharmaceutical benefit* specified in the prescription is to be supplied; and

 (ea) if paragraph (3A)(b) of this section applies to the prescription—the section of the chart is not completed using a computer program that operates, or may operate, to indicate on a prescription by default a brand of the pharmaceutical item that the pharmaceutical benefit has; and

 (f) if the patient is receiving treatment in or at an *approved hospital*—the chart specifies the day on which the chart’s period of validity ends under subsection 16AA(3A), which must be the last day of one of the following periods starting on the day the first prescription for a *Pharmaceutical benefit* is written in the chart:

 (i) 1 month;

 (ii) 4 months;

 (iii) 12 months; and

 (g) in any case—the section of the chart is completed before the end of the chart’s period of validity under subsection 16AA(3) or (3A).

Note: A section in a medication chart may set out fields that only need to have information filled in if the information is relevant to the particular prescription concerned.

Example: For paragraph (f), the first prescription is written in a medication chart on 11 June in a particular year. The day specified in the chart as the day on which the chart’s period of validity ends must be 10 July or 10 October in that year, or 10 June in the following year.

 (3A) For the purposes of subparagraph (3)(a)(i), the *RPBS prescriber* must write in the section of the chart:

(a) if:

(i) the prescription is prepared by handwriting the prescription on the section of the chart; or

(ii) the prescription is for the supply of a pharmaceutical benefit that has 4 or more drugs; or

(iii) the patient is receiving treatment in or at a residential care service and the medication chart is not an electronic medication chart; or

(iv) the prescription is for the supply of a pharmaceutical benefit that is specified by the Secretary, in writing, for the purposes of subparagraph 40(2A)(a)(iii) of the *National Health (Pharmaceutical Benefits) Regulations 2017;* or

 (v) the prescription is for the supply of a *Pharmaceutical benefit* listed under the heading “Various” in the *RPBS Schedule*;

 particulars sufficient to identify the pharmaceutical benefit; or

 (b) otherwise:

 (i) each drug that the *Pharmaceutical benefit* has; and

 (ii) if the *RPBS prescriber* considers that it is necessary for the medical treatment of the patient to identify a brand of the pharmaceutical item that the *Pharmaceutical benefit* has—the brand of the pharmaceutical item.

 (3B) If subparagraph (3A)(b)(ii) applies, the brand of the pharmaceutical item must be listed after the drugs that the pharmaceutical benefit has.

 (3C) Subsection (3A) does not apply to the extent that it would be contrary to a law of a State or Territory that would otherwise apply.

Completing section of medication chart—authority prescriptions

 (4) An *RPBS prescriber* completes a section of a medication chart in accordance with this subsection for a person for the purpose of writing an *authority prescription* if the section of the chart contains:

 (a) the authority approval number (if one is given); or

 (b) the *relevant streamlined authority code* for the *Pharmaceutical benefit* that is prescribed.

Authority prescriptions that have been authorised in accordance with certain authority required procedures

 (4A) Subparagraph (1)(b)(ii) does not apply to *authority prescriptions* that have been authorised in accordance with authority required procedures that are incorporated by reference into the circumstances determined for a *Pharmaceutical benefit* under subsection 85B(4) of the *National Health Act 1953*.

Note: If the authority required procedures referred to in subsection (4A) require a streamlined authority code or an authority approval number to be written on an authority prescription, and the code or number is not written on the authority prescription, the special patient contribution is not payable by the Commonwealth: see subsection 85B(4) of the *National Health Act 1953*.

 *Medication charts*

 (6) A *medication chart* is a chart in a form (if any) approved under subsection (7) that is used for prescribing, and recording the administration of, Pharmaceutical benefits to persons receiving treatment in or at a *residential care service* or a hospital, whether or not the chart :

 (a) is used for any other purpose; or

 (b) contains any other information.

Note: For paragraph (a), the chart may also be used (for example) to prescribe, and record the administration of drugs, medicines and other substances that are not Pharmaceutical benefits.

 (7) The form of a medication chart is approved if the Secretary (as defined in the *National Health Act 1953*) has approved it.

Electronic medication charts

 (8) An ***electronic medication chart*** is a medication chart in a form approved by the Secretary under subsection 41(5) of the *National Health (Pharmaceutical Benefits) Regulations 2017* for the purpose of writing an electronic prescription.

11C Writing prescriptions—additional requirements for all electronic prescriptions

 An *RPBS prescriber* writes an electronic prescription in accordance with this section if the *RPBS prescriber*:

 (a) includes in the metadata of the prescription:

 (i) the conformance identifier provided to the Australian Digital Health Agency in relation to the software used to prepare the prescription; and

 (ii) a unique identifier for the prescription generated by that software; and

 (b) states in the prescription:

 (i) the healthcare identifier (if any) assigned to the *RPBS prescriber*; and

 (ii) the healthcare identifier assigned to a healthcare provider organisation to which the *RPBS prescriber* is linked (within the meaning of the *Healthcare Identifiers Act 2010*).

11D Writing prescriptions—additional information that may be included in electronic prescriptions

 An electronic prescription may include either or both of the following:

 (a) the date of birth of the person for whom the *Pharmaceutical benefit* is prescribed;

 (b) the reason why the *Pharmaceutical benefit* is prescribed to that person.

12 When prescriptions are invalid

 A *prescription* is not a valid *Pharmaceutical benefit* if the *Medical Practitioner*, *Authorised Nurse Practitioner* or *Authorised Midwife*:

 (a) except where the *prescription* is a *medication chart prescription*, prescribes a *Pharmaceutical benefit* for a person in respect of whom another *prescription* for the same benefit has been written on the same day by the same *Medical Practitioner*, *Authorised Nurse Practitioner* or *Authorised Midwife*; or

 (b) prescribes, on the one form, a *Pharmaceutical benefit* that is a drug of addiction and another *Pharmaceutical benefit*, and directs that the supply of either *Pharmaceutical benefit* is to be repeated (but, if no repeats of either item are ordered, the *prescription* may be accepted provided that this is in accordance with the relevant State or Territory law); or

 (c) prescribes a narcotic drug for the *Medical Practitioner*, *Authorised Nurse Practitioner* or *Authorised Midwife* writing the *prescription*; or

 (d) prescribes on a *Standard Prescription Form* an item not listed in the *RPBS Schedule* or *PBS Schedule*; or

 (e) prescribes on a *Standard Prescription Form* a benefit in contravention of any of the restrictions set out in paragraph 7; or

 (f) where the prescription is by an *Authorised Nurse Practitioner* or *Authorised Midwife* for an *Eligible Person* — prescribes a *Pharmaceutical benefit* that is not available to the *Eligible Person* under the *PBS*.

Note: an RPBS prescriber who is an *Authorised Midwife* or an *Authorised Nurse Practitioner* may only prescribe a *Pharmaceutical benefit* listed on the *PBS* and a prescription by an *Authorised Midwife* or an *Authorised Nurse Practitioner* for a *Pharmaceutical benefit* that is not available on the *PBS* is not recognised under the *Scheme*, even if the *Pharmaceutical benefit* is available under the *Scheme* on the prescription of, say, an *Approved Medical Practitioner*.

13 Maximum quantity and repeats allowed

 The quantity and repeats for *Scheduled items* are to be confined to those specified in the *RPBS Schedule* or *PBS Schedule*. However, where inadequate, the *Medical Practitioner*, *Authorised Nurse Practitioner* or *Authorised Midwife* may seek *Prior Approval* to prescribe a quantity greater, or a greater number of repeats, than the maximum listed in the *RPBS Schedule* or *PBS Schedule*.

Note: an RPBS prescriber who is an *Authorised Midwife* or an *Authorised Nurse Practitioner* may only prescribe a *Pharmaceutical benefit* listed on the *PBS* and a prescription by an *Authorised Midwife* or an *Authorised Nurse Practitioner* for a *Pharmaceutical benefit* that is not available on the *PBS* is not recognised under the *Scheme*, even if the *Pharmaceutical benefit* is available under the *Scheme* on the prescription of, say, an *Approved Medical Practitioner*.

14 Prescribing outside the RPBS Schedule or PBS Schedule

 If a *Medical Practitioner* is of the clinical opinion that there are no therapeutic alternatives available in the *RPBS Schedule* or *PBS Schedule* for the treatment of an Eligible Person, the *Medical Practitioner* may seek *Prior Approval* from the *Commission* to prescribe an item not contained in those Schedules.

15 Medical Practitioner subject to this Scheme

 Where a *Medical Practitioner*, *Authorised Nurse Practitioner* or *Authorised Midwife* prescribes for an *Eligible Person*, the *Medical Practitioner*, *Authorised Nurse Practitioner* or *Authorised Midwife* shall be subject to the terms and conditions of this *Scheme* and the *Explanatory Notes*.

Note: an RPBS prescriber who is an *Authorised Midwife* or an *Authorised Nurse Practitioner* may only prescribe a *Pharmaceutical benefit* listed on the *PBS* and a prescription by an *Authorised Midwife* or an *Authorised Nurse Practitioner* for a *Pharmaceutical benefit* that is not available on the *PBS* is not recognised under the *Scheme*, even if the *Pharmaceutical benefit* is available under the *Scheme* on the prescription of, say, an *Approved Medical Practitioner*.

Part 3—Supply of Pharmaceutical Benefits

16 Supply of Pharmaceutical Benefits — Procedure by Community Pharmacists

 Subject to paragraph 16AAA (special arrangements) and paragraph 16A (continued dispensing), a *Community Pharmacist* is required to supply a *Pharmaceutical benefit* only upon the surrender of:

 (a) a valid *Standard Prescription Form*; or

 (b) a valid *Authority Prescription Form*; or

 (c) a valid *repeat authorisation form* presented with a duplicate *prescription* in accordance with the requirements under the *PBS*; or

 (d) a valid *medication chart prescription*;

Note: The Commonwealth introduced medication chart prescribing (MCP) in stages. Firstly there was a trial of MCP in certain residential care services and then it was adopted for residential care services. Secondly, on 1 April 2015, a trial of MCP at certain hospitals commenced. The intention in the RPBS is to ensure MCP under the RPBS can only occur for patients in residential care services or hospitals where it could occur in respect of those patients under the *National Health (Pharmaceutical Benefits) Regulations 2017.*

 provided that such documents are in accordance with State or Territory law and this *Scheme* and the *Explanatory Notes*, and with any requirements which the *Department* or the *Commission*, from time to time, notifies.

16AAA Pharmaceutical benefits supplied under a special arrangement

(1) A *Community Pharmacist* will be required to supply a *Pharmaceutical*

 *benefit* to an *Eligible Person* under a *special arrangement* if:

(a) the supply is made in accordance with the conditions specified in the *National Health (COVID‑19 Supply of Pharmaceutical Benefits) Special Arrangement 2020* as in force from time to time:

(i) as if the supply under the *Scheme* is a supply covered by the instrument; and

(ii) the instrument has effect under subsections (2), (3), (4), (5), (6),

 (7), (8), (9), (10) and (11) of this section; and

(iii) to the extent that those conditions are applicable to the supply;

 and

(iv) the supply of the *Pharmaceutical benefit* occurs before the repeal of the *National Health (COVID‑19 Supply of Pharmaceutical Benefits) Special Arrangement 2020;*

(b) the supply otherwise conforms to this section.

(2) For the purposes of paragraph (1)(a) of this section, the *National Health (COVID‑19 Supply of Pharmaceutical Benefits) Special Arrangement 2020* has effect in accordance with the following table.

| **Modified effect of the *National Health (COVID‑19 Supply of Pharmaceutical Benefits) Special Arrangement 2020* instrument** |
| --- |
| **Item** | **Column 1****The instrument has effect as if a reference to …** | **Column 2****were a reference to …** |
| 1 | a paper‑based repeat authorisation  | a *repeat authorisation form* |
| 2 | a PBS prescriber | a person who prescribes a *Pharmaceutical benefit* under the *Scheme* |
| 3 | a pharmaceutical benefit | a *Pharmaceutical benefit* |
| 4 | an approved hospital authority  | an *Approved Hospital Authority*  |
| 5 | an approved pharmacist | a *Community Pharmacist* |
| 6 |  a CTS claim | a claim under the *claims rules* |
| 7 | Part VII of the Act | the *Scheme* |
| 8 | section 44 of the Regulations  | section 16 of the *Scheme*  |
| 9 | subsections 40(1), (2) and (2A) of the Regulations | subsections 11A(1) and (1A) of the *Scheme* |
| 10 | subsection 40(2) of the Regulations  | subsection 11A(1) of the *Scheme* |

*Further modifications of the instrument*

(3) The *special arrangement* referred to in paragraph (1)(a) has effect as if the definition of “approved hospital authority” in subsection 6(1) of the instrument is omitted.

(4) The *special arrangement* referred to in paragraph (1)(a) has effect as if the definition of “approved hospital authority dispenser” in subsection 6(1) of the instrument is replaced with the following:

***approved hospital authority dispenser*** means the *Community Pharmacist* or *approved medical practitioner* by whom, or under whose supervision, a *Pharmaceutical benefit* supplied by an *Approved Hospital Authority* will be dispensed.

(5) The *special arrangement* referred to in paragraph (1)(a) has effect as if the definition of “CTS claim” in subsection 6(1) of the instrument is omitted.

(6) The *special arrangement* referred to in paragraph (1)(a) has effect as if the definition of “medication chart prescription” in subsection 6(1) of the instrument is replaced with the following:

***medication chart prescription*** has the same meaning as in the *Scheme*.

(7) The *special arrangement* referred to in paragraph (1)(a) has effect as if the definition of “paper‑based prescription” in subsection 6(1) of the instrument is replaced with the following:

***paper‑based prescription*** has the same meaning as in the *Scheme*.

(8) The *special arrangement* referred to in paragraph (1)(a) has effect as if section 8 of the instrument is replaced with the following:

**8 Application of the Scheme**

A provision of the *Scheme* applies subject to this Special Arrangement.

(9) The *special arrangement* referred to in paragraph (1)(a) has effect as if subsection 9(1) was omitted and replaced with the following:

(1) Division 2 of Part 2 of this Special Arrangement applies to the supply of a pharmaceutical benefit by an approved supplier based on a paper‑based prescription (excluding a medication chart prescription) written as the result of a telehealth attendance or phone attendance provided on or after 20 March 2020 to which an item in a *Fee Schedule* (a document incorporated as in force from time to time for the purposes of the *Treatment Principles*) applies.

(10) The *special arrangement* referred to in paragraph (1)(a) has effect as if subsection 9(4) of the instrument is omitted.

(11) The *special arrangement* referred to in paragraph (1)(a) has effect as if subsection 10(4) of the instrument is replaced with the following:

(4) If the prescription is or would be an *authority prescription*, the supplier may supply the *Pharmaceutical benefit* under this section only if *prior approval* has been obtained.

16AA Supply of pharmaceutical benefit on basis of medication chart prescription

 (1) A *Pharmaceutical benefit* may only be supplied on the basis of a *medication chart prescription* by:

 (a) if the person in respect of whom the *Pharmaceutical benefit* is to be supplied is receiving treatment in or at a *residential care service* – a *Community Pharmacist*; or

 (b) if the person in respect of whom the *Pharmaceutical benefit* is to be supplied is receiving treatment in or at an *approved hospital*—a *Community Pharmacist* or the *Approved Hospital Authority*.

 (2) A *Community Pharmacist* may supply a *Pharmaceutical benefit* on the basis of a *medication chart prescription* only if:

 (a) the *Community Pharmacist* has seen:

 (i) the *medication chart* by which the prescription was written; or

 (ii) a copy of so much of the chart as would indicate that subsections 11B(3) and (4) (if applicable) have been complied with; and

 (b) the date on which the *Pharmaceutical benefit* is supplied is:

 (i) during the period of validity of the *medication chart*; and

 (ii) no later than the stop date (if any) indicated in the prescription; and

 (c) the *Community Pharmacist* writes on the *medication chart* or the copy of the chart, the following for the supply:

 (i) the *Community Pharmacist’s* name and any approval number under section 16 of the *National Health (Pharmaceutical Benefits) Regulations 2017*;

 (ii) an identification number for the supply;

 (iii) the date on which the *Pharmaceutical benefit* is supplied.

 (3) For paragraph (2)(b), the period of validity of a *medication chart* for a person receiving treatment in or at a *residential care service*:

 (a) starts on the day in a calendar month (the ***first calendar month***) when the first prescription for a *Pharmaceutical benefit* is written in the *medication chart*; and

 (b) ends on the last day of the third calendar month that starts after the first calendar month.

Example: The first prescription is written in a medication chart on 11 June. The period of validity of the medication chart starts on 11 June and ends on 30 September.

Note: ***calendar*** ***month*** is defined in section 2B of the *Acts Interpretation Act 1901*.

 (3A) For paragraph (2)(b), the period of validity of a *medication chart* for a person receiving treatment in or at a hospital:

 (a) starts on the day when the first prescription for a *Pharmaceutical benefit* is written in the chart; and

 (b) ends at the end of the day specified in the chart as the day on which the chart’s period of validity ends (see paragraph 11B(3)(f)).

 (4) A *Community Pharmacist* may supply up to a maximum quantity of a Pharmaceutical item or *Pharmaceutical benefit* more than once on the basis of a particular *medication chart prescription* for the *Pharmaceutical benefit* only if:

 (a) the prescription indicates that an ongoing supply of the *Pharmaceutical benefit* is authorised for the period of validity of the chart; or

 (b) the prescription indicates a stop date for the supply of the *Pharmaceutical benefit* and, based on the dose and frequency of administration of the *Pharmaceutical benefit* indicated in the prescription, more than one supply of a maximum quantity of the Pharmaceutical item or *Pharmaceutical benefit* is needed before the stop date is reached.

Note: See paragraph 85A(2)(a) of the *National Health Act 1953*, the PBS Schedule, and the RPBS Schedule, in relation to maximum quantities of pharmaceutical items or pharmaceutical benefits.

 (5) If paragraphs (4)(a) and (b) do not apply, a *Community Pharmacist* may only supply the quantity of the *Pharmaceutical benefit* needed to give effect to the prescription, up to a maximum quantity of the pharmaceutical item or *Pharmaceutical benefit*.

Note: The following information entered in the prescription may also indicate the quantity of the Pharmaceutical benefit that is needed:

(a) the dose and frequency of administration of the Pharmaceutical benefit;

(b) the date of prescribing, or the start date (if any) for administration of the Pharmaceutical benefit;

(c) the stop date (if any) for administration of the Pharmaceutical benefit.

 (6) However, for a supply:

 (a) on the basis of a prescription mentioned in paragraph (4)(a); or

 (b) mentioned in paragraph (5);

 a *Community Pharmacist* may supply up to a maximum quantity of the pharmaceutical item or *Pharmaceutical benefit* even if the period of validity of the *medication chart* will end before administration of that quantity in accordance with the prescription would finish.

Continued Dispensing

16A When Pharmaceutical benefits may be supplied by Community Pharmacists without prescription

Pharmaceutical benefits covered by PBS and National Health Act section 89A instruments

 (1) A *Community Pharmacist* may, at or from premises in respect of which the pharmacist is for the time being approved under the *National Health Act 1953*, supply a *Pharmaceutical benefit* to an *Eligible Person* without a *prescription* for that supply if:

 (a) the *Pharmaceutical benefit* is covered by the *Scheme* and an instrument in force under subsection 89A(3) of the *National Health Act 1953*; and

 (b) the supply is made in accordance with the conditions specified in the instrument:

 (i) as if the supply under the *Scheme* is a supply covered by the instrument; and

 (ii) as the instrument has effect under subsection (1B) of this section; and

  (c)  the supply otherwise conforms to this section.

*Certain Pharmaceutical benefits not covered by PBS*

 (1A) A *Community Pharmacist* may, at or from premises in respect of which the pharmacist is for the time being approved under the *National Health Act 1953*, supply a *Pharmaceutical benefit* to an *Eligible Person* without a *prescription* for that supply if:

 (a) the *Pharmaceutical benefit* is specified in the table in Schedule 2; and

 (b) the supply is made in accordance with the conditions specified in the *National Health (Continued Dispensing – Emergency Measure) Determination 2025*:

 (i) as if the supply under the *Scheme* is a supply covered by that instrument; and

 (ii) as that instrument has effect under subsection (1B) of this section; and

 (iii) to the extent that those conditions are applicable to the supply; and

 (c) the supply otherwise conforms to this section.

*Modified effect of National Health Act section 89A instruments*

 (1B) For the purposes of subparagraphs (1)(b)(ii) and (1A)(b)(ii) of this section, an instrument in force under subsection 89A(3) of the *National Health Act 1953* has effect in accordance with the following table.

| **M****odified effect of National Health Act section 89A instruments** |
| --- |
| **Item** | **Column 1****The instrument has effect as if a reference to …** | **Column 2****were a reference to …** |
| 1 | a PBS prescriber | a person who prescribes a *Pharmaceutical benefit* under the *Scheme* |
| 2 | a pharmaceutical benefit | a *Pharmaceutical benefit* |
| 3 | a pharmaceutical item | a *Pharmaceutical benefit* |
| 4 | an approved pharmacist | a *Community Pharmacist* |
| 5 | paragraph 85A(2)(a) of the Act | the *Scheme* |
| 6 | paragraph 89A(3)(a) of the Act | the *Scheme* |
| 7 | Part VII of the Act | the *Scheme* |
| 8 | subsection 89A(1) of the Act | the *Scheme* |
| 9 | a statement that particular conditions are satisfied | a statement that particular conditions, as they have effect under this subsection, are satisfied |

*Other matters*

 (2) If a *Community Pharmacist* makes a supply in accordance with subsection (1) or (1A), then this *Scheme* applies in relation to the supply as if the *Eligible Person* had presented the pharmacist with a *prescription* that had been written in accordance with this *Scheme*.

 (3) The supply of a *Pharmaceutical benefit* in accordance with this section is a *continued dispensing supply*.

 (4) A *Community Pharmacist* must not supply a *Pharmaceutical benefit* under this section unless the pharmacist writes on the repeat authorisation form for the supply:

 (a) the pharmacist’s name and approval number under section 16 of the *National Health (Pharmaceutical Benefits) Regulations 2017*; and

 (b) an identification number for the supply; and

 (c) the date on which the *Pharmaceutical benefit* is supplied by the pharmacist.

Note: a failure to observe these requirements means the supply is not a *continued dispensing supply*.

 (5) For a *continued dispensing supply* a *Community Pharmacist* or *Approved Medical Practitioner* must collect the following information at the time of supply:

 (a) information about whether the patient is, at the time of the supply:

 (i) a *concessional beneficiary* or a dependant of a *concessional beneficiary*; or

 (ii) the holder of a *concession card* or *entitlement card*;

 (b) for a person mentioned in subparagraph (a)(i)—the number specified on a card, issued by the Commonwealth, as an entitlement number (however described) in relation to the person;

 (c) for a person mentioned in subparagraph (a)(ii)—the number of the *concession card* or *entitlement card*.

 (6) The *Community Pharmacist* or *Approved Medical Practitioner* must include the information collected under subsection (5) in the claim for a payment from the Commonwealth in relation to the supply using the Claims Transmission System, within the meaning given by subsection 99AAA(1) of the *National Health Act 1953*.

Note: a failure to observe these requirements means the supply is not a *continued dispensing supply*.

 (7) For the supply of a *Pharmaceutical benefit* by a *Community Pharmacist* on the basis of a previous *prescription* from a *PBS prescriber* or *RPBS prescriber*, if the *PBS prescriber* or *RPBS prescriber* directed in the *prescription* the supply on one occasion of a quantity or number of units of the *Pharmaceutical benefit* allowable under subsection 88(6) of the *National Health Act 1953*, instead of directing a repeated supply, the direction does not apply for the purposes of the *continued dispensing supply*.

 (8) If, for a *continued dispensing supply*, a *Pharmaceutical benefit* is supplied a number of times greater than the number specified in the *prescription*, then subject to subsection 51(2) of the *National Health (Pharmaceutical Benefits) Regulations 2017* (the regulations), subregulation (3) or (4) of those regulations applies as if:

 (a) the person had presented the supplier with a *prescription* that:

 (i) had been written by a *PBS prescriber* or *RPBS prescriber* in accordance with the *National Health Act 1953*, the regulations and the *Scheme*; and

 (ii) did not include a *medicare number*; and

 (iii) did not direct a repeated supply of a *Pharmaceutical benefit*; and

 (b) subparagraphs (3)(b)(ii) and (c)(ii) or (4)(b)(ii) and (c)(ii), of the regulations, were omitted, and the words ‘immediate supply necessary’ were required to be written on the repeat authorisation form for the supply; and

 (c) subparagraphs (3)(b)(iii) and (c)(iii) or (4)(b)(iii) and (c)(iii), of the regulations, were omitted, and the supplier were required to sign the repeat authorisation form mentioned in paragraph (b).

 (9) A *Community Pharmacist* must use a *repeat authorisation form* for the purposes of making a claim for a payment from the Commonwealth under section 99AAA of the Act in relation to a *continued dispensing supply*, however, the pharmacist must not use the form for authorising a repeated supply of the pharmaceutical benefit under this section.

 (10) For a *continued dispensing supply* a *Community Pharmacist* is to obtain, from the person receiving the *Pharmaceutical benefit* (whether or not for the person’s own use), a written acknowledgement that the person has received the benefits but if it is not practicable for the pharmacist to obtain, from the person a written acknowledgement, the pharmacist must write on the *repeat authorisation form* for the supply:

 (a) the date on which the *Pharmaceutical benefit* were supplied by the pharmacist; and

 (b) the reason why it was not practicable for the pharmacist to obtain the written acknowledgement.

16AB Information about status of person—continued dispensing and medication chart prescriptions

 (1) This section applies in relation to:

 (a) the supply of a *Pharmaceutical benefit* to a person (the ***patient***) by a *Community Pharmacist* (the ***supplier***) under subsection 16A (continued dispensing); and

 (b) the supply of a *Pharmaceutical benefit* by a *Community Pharmacist*, on the basis of a *medication chart prescription* written for a person (the ***patient***);

 (2) The supplier must collect the following information at the time of supply:

 (a) information about whether the patient is, at the time of the supply:

 (i) a *concessional beneficiary* or a dependant of a *concessional beneficiary*; or

 (ii) the holder of a *concession card* or *entitlement card*;

 (b) for a person mentioned in subparagraph (a)(i)—the number specified on a card, issued by the Commonwealth, as an entitlement number (however described) in relation to the person;

 (c) for a person mentioned in subparagraph (a)(ii)—the number of the *concession card* or *entitlement card.*

 (3) The supplier must include the information collected under subsection (2) in the claim for a payment from the Commonwealth in relation to the supply using the Claims Transmission System, within the meaning given by subsection 99AAA(1) of the *National Health Act 1953*.

17 Substitution of lesser priced alternative brand of drug

 Where a valid *prescription*, issued by a *Medical Practitioner, Authorised Nurse Practitioner* or *Authorised Midwife*, prescribes a brand of drug listed on the *PBS* or *RPBS Schedule*, a *Community Pharmacist* may substitute, with the approval of the prescriber, a lesser priced alternative *PBS* or *RPBS* listed brand of the drug in lieu of the brand prescribed and shall endorse the original, duplicate and repeat authorisation accordingly.

Note: an RPBS prescriber who is an *Authorised Midwife* or an *Authorised Nurse Practitioner* may only prescribe a *Pharmaceutical benefit* listed on the *PBS* and a prescription by an *Authorised Midwife* or an *Authorised Nurse Practitioner* for a *Pharmaceutical benefit* that is not available on the *PBS* is not recognised under the *Scheme*, even if the *Pharmaceutical benefit* is available under the *Scheme* on the prescription of, say, an *Approved Medical Practitioner*.

18 Community Pharmacist to be satisfied as to entitlement

 (a) A *Community Pharmacist* shall not supply a *Pharmaceutical benefit* to a person on terms that are appropriate for the supply of a *Pharmaceutical benefit* to a holder of a *Repatriation Health Card ‑ For All Conditions*, a *Repatriation Health Card ‑ For Specific Conditions* or a *Repatriation Pharmaceutical Benefits Card*, unless the *Community Pharmacist* is satisfied that the person is entitled to receive the *Pharmaceutical benefit* on those terms.

 (b) Without limiting the generality of subparagraph (a), a *Community Pharmacist* may refuse to supply a *Pharmaceutical benefit* to a person on terms that are appropriate for the supply of the *Pharmaceutical benefit* to a holder of a *Repatriation Health Card ‑ For All Conditions* **,** a *Repatriation Health Card ‑ For Specific Conditions* or a *Repatriation Pharmaceutical Benefits Card*, unless the person produces such a card to the *Community Pharmacist* that indicates that the person is entitled to receive the *Pharmaceutical benefit* on those terms.

19 Dispensing of deleted items

 *Prescriptions*, including repeat authorisations, for items deleted from the *RPBS Schedule* or *PBS Schedule* may not be dispensed as *Pharmaceutical benefits* as from the date of effect of deletion, unless the prescriptions for the items comply with *Prior Approval* arrangements under this Part.

20 Use of forms as notified by the Department or the Commission

 When supplying a *Pharmaceutical benefit* under this *Scheme* a *Community Pharmacist* will use and issue such forms, as are notified by the *Department* or the *Commission* from time to time, in the manner notified by the *Department* or the *Commission*.

21 Financial responsibility

 (1) In respect of each *Pharmaceutical benefit* provided to an *Eligible Person* under this *Scheme*, the *Commission* will accept financial responsibility for:

 (a) subject to (b) all of the dispensed price but the *co‑payment* that would be payable by the person if the person were a *concessional beneficiary*; or

Note 1: (a) deems the person to be a *concessional beneficiary* for the purposes of working out the *co‑payment*.

Note 2: *co‑payments* not covered by the *pension supplement amount*, *veterans supplement* or *MRCA supplement* or *war widow/war widower pension* may be reimbursed under Part 5A up to the safety net amount for a person.

 (b) if the *safety net* applies to the person, all of the dispensed price.

21A Dispensed Price for RPBS Schedule Pharmaceutical benefits

 (1) The *Commission* is to decide the *dispensed price* for *Pharmaceutical benefits* included in the *RPBS Schedule* and the *Departmen*t is to notify a *dispensed price* decided by the *Commission*.

Note (1): in practice a delegate of the *Commission* could decide the dispensed price.

Note (3): sections 4 and 5 explain the process of notification for the purposes of the *Scheme.*

 (2) The *dispensed price* in (1) is to be comprised of:

 (a) the ex manufacturer price – being the price the *Commission* and the responsible person for the brand of the *Pharmaceutical benefit* have agreed, by reference to the quantity of the *Pharmaceutical benefit*,is to be the price at which the manufacturer sells the *Pharmaceutical benefit* in the context of the *Scheme* (approved ex manufacturer price); and

Note: in practice a delegate of the *Commission* could enter into the agreement.

 (b) the following amounts worked out as if the *Pharmaceutical benefit* is included in the PBS and the amount worked out under the *PBS* and the *Eighth Community Pharmacy Agreement* except that the approved ex manufacturer price is ascertained under the *Scheme*:

 (i) the wholesale mark‑up – being the mark‑up on the approved ex manufacturer price of a ready‑prepared *Pharmaceutical benefit* (approved wholesale price);

 (ii) the administration, handling and infrastructure fee;

Note: previously this fee was known as the pharmacy mark‑up.

 (iii) the dispensing fee (for a ready‑prepared *Pharmaceutical benefit* or a extemporaneously‑prepared *Pharmaceutical benefit* (as the case may be));

 (iv) any dangerous drug fee (for a ready‑prepared *Pharmaceutical benefit*).

Note: see clause 3 (Commonwealth Price) of the *Eighth Community Pharmacy Agreement* for the amounts mentioned above.

22 Refund in certain circumstances

 (1) Where:

 (a) a *Community Pharmacist* charges an *Eligible Person* an amount in respect of the provision of a *Pharmaceutical benefit*; and

 (b) information indicating the person’s eligibility under this *Scheme* was not supplied to the *Community Pharmacist*; and

 (c) the *Commission* is satisfied that, in the circumstances, the person should be treated as if the relevant information had been supplied,

 the person is entitled to be paid by the Commonwealth an amount equal to any amount that the person paid that would not have been payable if the relevant information had been supplied.

23 Expenses incurred in obtaining Pharmaceutical Benefits while not in receipt of a pharmaceutical allowance

 (1) Where a person would have been eligible to receive a pharmaceutical allowance under paragraph 118A(1)(c) of the *Veterans’ Entitlements Act 1986* during a period, but the *Department*:

 (a) did not have the information needed to enable the *Commission* to make payment of the pharmaceutical allowance; and

 (b) has obtained that information since that period and after 30 June 1992; and

 the person:

 (c) was not in receipt of that allowance during that period; and

 (d) has incurred expenses in obtaining *Pharmaceutical benefits* during that period which could be obtained under this *Scheme*; and

 (e) has provided material which satisfies the *Commission* that the person has incurred those expenses,

 the *Commission* may reimburse the person for any or all of those expenses. The maximum amount which may be reimbursed is the amount that the person would have been entitled to receive by way of pharmaceutical allowance during that period had the *Department* had the information needed to enable the *Commission* to make payment of the allowance.

Part 4—Claims by Community Pharmacists

24 Lodgement of Claims by Community Pharmacists

 Claims by *Community Pharmacists* under this Part shall be made in accordance with section 99AAA of the *National Health Act 1953* as though references in that section, and in the rules made under that section which relate to the supply of and payment for *Pharmaceutical benefits* under that Act and its Regulations, were references to the supply of, and payment for, *Pharmaceutical benefits*, except that:

 (a) *prescriptions* for the supply of *Pharmaceutical benefits* under this Part shall be marked in the S section or S sections (as defined in those rules) with one or more serial numbers allotted in respect of each *Pharmaceutical benefit* commencing at “**R1”** in each claim and continuing consecutively in respect of that claim;

 (b) these *prescriptions* shall be collected into one bundle, separate to the four bundles provided for in those rules, with the prescriptions sorted into the order of the serial numbers allocated under subparagraph (a), with the least serial number at the top of the bundle; and

 (c) the information to be provided to the Secretary to the Department that administers the *National Health Act 1953*, in respect of each supply of a *Pharmaceutical benefit* shall include a Form Category (within the meaning of the schedule to those rules) with a value of “**8”** where the *Pharmaceutical benefit* was supplied on an original authority prescription or “**9”** where the *Pharmaceutical benefit* was supplied on a repeat authority prescription, and a Payment Category (within the meaning of that schedule) with a value of “**4”.**

Note (1): this provision incorporates into the *Scheme*, among other relevant “*National Health Act 1953* requirements” (particularly the requirements in the *claims rules* made under subsections 98AC(4) and 99AAA(8) of the *National Health Act 1953*), the requirement for a claimant to include a “supply certification form” with a claim (manual and electronic).

Note (2): if a claim is made electronically, the supply certification form is to be given electronically (*claims rules*).

Note (3): for electronic claims, prescriptions need not be provided (*claims rules*).

25 Claims Requirements and Payment

 (1) The payment of a claim under the *Scheme* is subject to:

 (a) compliance with the *Scheme*, in particular section 24; and

 (b) submission of a completed supply certification form under the *claims rules*.

Part 5—Payments to Community Pharmacists

26 Payment of Dispensed Price

 The amount payable to a *Community Pharmacist* for the supply of a *Pharmaceutical benefit* under the *Scheme* is the *dispensed price*.

Note: the dispensed price includes a dispensing fee.

30 Fees not payable in some circumstances

 The *dispensed price* may not be payable to a *Community Pharmacist* where that person does not satisfy the requirements of paragraph 18 and supplies *Pharmaceutical benefits* to a person who is not an *Eligible Person*.

31 Community Pharmacist not entitled to demand or receive payments

 A *Community Pharmacist* is not entitled to demand of, or receive from, a person in receipt of a *Pharmaceutical benefit*, payment in money or a valuable consideration for goods and services rendered under this *Scheme* except:

 (a) for goods or services that are provided in an emergency; or

 (b) for payment of an after‑hours fee; or

 (c) for payment for packaging material, postage or freight; or

 (d) for payment that represents the required payment under the *PBS* of the price difference between the drug prescribed and supplied and the lowest priced brand of the same drug listed on the *PBS Schedule*; or

 (e) where payment represents the difference between the Commonwealth’s financial responsibility for the provision of the *Pharmaceutical benefit* and the dispensed price of the *Pharmaceutical benefit* supplied.

32 Community Pharmacist to issue receipt where certain payments received

 Where a payment is received, under any of subparagraphs 31(a), (b), (c) or (d), from a person in receipt of a *Pharmaceutical benefit*, the *Community Pharmacist* is required to issue that person an official receipt which states:

 (a) the goods and/or services provided; and

 (b) the date of receipt of those goods and/or services by the person.

32A Additional community supply support payment

 (1) In this section:

***increased maximum quantity***, of a *Pharmaceutical benefit*, means the maximum quantity or number of units of the benefit, or of a *pharmaceutical item* in the benefit, that may, in 1 prescription, be directed to be supplied on any 1 occasion, for a *relevant purpose*, under and in accordance with this *Scheme* or the *Treatment Principles*, part 5.7.

***increased maximum quantity prescription*** means a prescription directing the supply, on any 1 occasion, of the *increased maximum quantity* of a *Pharmaceutical benefit*.

***NHA*** means the *National Health Act 1953*.

***NHA instrument*** means the instrument made under paragraph 98B(1)(b) of the *NHA*.

***relevant purpose***, for a *Pharmaceutical benefit*, means a purpose, mentioned in the *PBS Schedule* or *RPBS Schedule* in relation to the benefit, thatincludes the phrase “The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient”.

***Schedule equivalent***—a *Pharmaceutical benefit* is *Schedule equivalent* to another *Pharmaceutical benefit* if the *PBS Schedule* or *RPBS Schedule* states that the benefits are equivalent.

 (2) The *Commission* is to pay an amount of money (an ***ACSS payment***)to a *Community Pharmacist* for each supply by the pharmacist of a *Pharmaceutical benefit*:

 (a) on or after 1 April 2024; and

 (b) under, and in accordance with, this *Scheme* or the *Treatment Principles*, part 5.7.

unless the supply is a supply mentioned in paragraph 5(a), (b), (c), (d), (e) or (f) of the *NHA instrument*.

 (3) If an *ACSS payment* is payable for a supply, the amount of the payment is:

(a)if subsection (4) or (5) applies to the supply—the amount mentioned in paragraph 6(1)(b) of the *NHA instrument*; or

 (b) in any other case—the amount mentioned in paragraph 6(1)(a) of the *NHA instrument*.

 (4) This subsection applies to a supply of a *Pharmaceutical benefit* to an *Eligible Person* for which an *ACSS payment* is payable if:

(a)the supply is made upon an *increased maximum quantity prescription* directing the supply of:

 (i) the benefit; or

(ii)another *Pharmaceutical benefit* that is *Schedule equivalent* to the benefit; and

 (b) the supply is of the *increased maximum quantity* of the benefit.

 (5) This subsection applies to a supply of a *Pharmaceutical benefit* to an *Eligible Person* for which an *ACSS payment* is payable if:

(a)the supply is made in accordance with section 16A; and

 (b) the immediately preceding supply to the person of the benefit, or of another *Pharmaceutical benefit* that is *Schedule equivalent* to the benefit, was made upon an *increased maximum quantity prescription* directing the supply of:

(i)the benefit; or

 (ii) another *Pharmaceutical benefit* that is *Schedule equivalent* to the benefit; and

(c)both the supplies mentioned in paragraphs (a) and (b) are of the *increased maximum quantity* of the relevant *Pharmaceutical benefit*.

Part 5A—Pharmaceutical Reimbursement

Definitions:

 In this Part:

***member*** means a person eligible under the *MRCA Pharmaceutical Benefits Scheme* for the payment known as the “pharmaceutical reimbursement”.

***veteran*** means an *Eligible Person* eligible for payment of a *pharmaceutical reimbursement*.

33

 The*Commission* may, subject to this Part, accept financial responsibility for the *pharmaceutical reimbursement*.

Note: if the *Commission* accepts financial responsibility for a cost in relation to the provision of a *Pharmaceutical benefit* to an *Eligible Person*, the Commonwealth pays that cost.

34

 The pharmaceutical reimbursementis a financial amount that would compensate an *Eligible Person* for out‑of‑pocket expenses:

 (a) that the person incurred in respect of a *Pharmaceutical benefit* provided under this *Scheme*; or

 (b) that the person incurred in respect of a *Pharmaceutical benefit* provided other than under this *Scheme* but provided on or from a date when the *Commission* accepted liability to provide treatment to the person under the *Act*.

Note 1: under the *Acts Interpretation Act 1901* words in the singular number (e.g. *Pharmaceutical benefit*) include the plural and words in the plural number include the singular.

Note 2: paragraph (b) covers what are known as “MEPIs” (Medical Expenses Privately Incurred). Under the *Act* eligibility for treatment can be backdated for 3 months before a claim for pension is received and treatment costs incurred in that period e.g. *co‑payments* for *Pharmaceutical benefits*, may be met by the *Department*.

35

 The amount of pharmaceutical reimbursement is worked out under 39.

36 Eligibility for Payment of Pharmaceutical Reimbursement

 (1) To be eligible for payment of the pharmaceutical reimbursementan *Eligible Person* must:

 (a) have rendered qualifying service; and

 (b) suffer from an *accepted disability*; and

 (c) receive pension under Part II or Part IV of the *Act* in respect of the *accepted disability.*

 (2) For the purposes of (1)(c), a person is taken to receive pension under Part II or Part IV of the *Act* if, apart from section 25A, Division 5A of Part II and section 74 of the *Act*, the person would receive a rate of pension greater than nil.

37 Calculation of annual value of pharmaceutical allowance component of Pension Supplement, Veterans Supplement, MRCA supplement

 The annual value of the pharmaceutical allowance component is calculated as follows:

 (a) for a *veteran* in receipt of *veterans supplement* or *MRCA supplement* at different times throughout the year, the amount of $6 per fortnight, indexed according to section 198F of the *Act*:

 (i) as if the amount of $6 is the dollar amount in subsection 198F(1);

 (ii) since September 2009 (i.e. once annually since 1 January 2010), calculated at a daily rate and valued according to the number of days in the calendar year *veterans supplement* or *MRCA supplement* was payable;

 (b) subject to (c), for a *veteran* in receipt of an *income support payment* or an *income support payment under the Social Security Act 1991* that, respectively, attracts *pension supplement,* or *social security pension supplement* greater than the basic amount of *pension supplement*, the amount of $6 per fortnight, indexed according to Division 18 of Part IIIB of the *Act*:

 (i) as if the amount of $6 is an amount of PS rate (pension supplement rate) in Item 1A of the CPI Indexation Table in section 59B;

 (ii) since September 2009 (i.e. each 20 March and 20 September commencing 20 March 2010), calculated at a daily rate and valued according to the number of days in the calendar year *pension supplement* was payable;

 Note: this provision could also apply to a veteran who is a member of a couple.

 (c) for a *veteran* in receipt of *pension supplement* who is a member of a couple:

 (i) if the veteran's partner does not receive an *income support payment* that attracts *pension supplement* or an *income support payment under the Social Security Act 1991* that attracts *social security pension supplement* greater than the basic amount of *pension supplement*—50% of the amount in (b); or

 (ii) if the veteran and partner are an illness separated couple—the amount in (b); or

 (iii) if the veteran and partner are not an illness separated couple but the veteran's partner is a *veteran* or a *member*—50% of the amount in (b);

 (d) for a *veteran* who is a war widow/war widower—pensioner, the amount of $6 per fortnight, indexed according to Division 18 of Part IIIB of the *Act*:

 (i) as if the amount of $6 is an amount of PS rate (pension supplement rate) in Item 1A of the CPI Indexation Table in section 59B;

 (ii) since September 2009 (i.e. each 20 March and 20 September commencing 20 March 2010), calculated at a daily rate and valued according to the number of days in the calendar year the person was a war widow/war‑widower—pensioner.

Note: a pharmaceutical allowance component calculated under (d) may be in addition to a pharmaceutical allowance component calculated under (b) or (c) and the sum of all the pharmaceutical allowance components could reduce the amount of the pharmaceutical reimbursement.

Note: the following terms are defined in the *Act*:

***member of a couple***‑5E(2).

***partner***–5E(1).

***war widow/war‑widower—pensioner***–5Q(1).

38 Payment of Pharmaceutical Reimbursement

 (1) On and after 1 January 2013 the *pharmaceutical reimbursement* is payable to a person eligible for it under this Part.

 (2) Subject to (3), the *pharmaceutical reimbursement* is payable in the first quarter in each calendar year in respect of *co‑payments* the person made for a *Pharmaceutical benefit* under this *Scheme* in the previous calendar year – not being a calendar year before 1 January 2012.

Note: calendar year is defined in section 2B of the *Acts Interpretation Act 1901.*

 (3) The *pharmaceutical reimbursement* is not payable for a person in the first quarter in a calendar year as mentioned in (2) if the data necessary to calculate the payment for the person is not available to the *Department* in which case the *pharmaceutical reimbursement* is payable to the person as soon as practicable after the data is available.

38A Five Year Limit on Payment of Pharmaceutical Reimbursement

 (1) Unless the *Commission* is of the opinion that there are special circumstances, a *pharmaceutical reimbursement* shall not be paid in respect of *co‑payment*s incurred by a person more than 5 calendar years before the *Commission* decision to accept financial responsibility for the *pharmaceutical reimbursement* for the person.

 (2) If the *Commission* decides there are special circumstances in relation to a person, then it is to determine a date on and from which *co‑payments* are to be counted for the *pharmaceutical reimbursement* for the person.

39 Pharmaceutical Reimbursement Calculator

 (1) The *pharmaceutical reimbursement* for an *Eligible Person* is worked out as follows:

 *Step 1* add the *co‑payments* for the *Pharmaceutical benefits* incurred by the person in the previous calendar year (sum of *co‑payments)* up to the threshold of payments according to the *safety net* and disregarding any uncounted *co‑payment*.

 *Step 2* compare the sum of *co‑payments* with the sum of the pharmaceutical allowance component of the *veterans supplement, MRCA supplement,* *pension supplement* and *war widow/war widower pension* payable to the person in respect of the previous calendar year.

 *Step 3* if the sum of *co‑payments* (amount 1) exceeds the sum of the pharmaceutical allowance component of the *veterans supplement, MRCA supplement,* *pension supplement* and *war widow/war widower pension* payable (amount 2), the amount by which amount 1 exceeds amount 2 is the pharmaceutical reimbursement for the person.

Note: the amount of any of these payments may be zero.

40 Uncounted Co‑Payment

 (1) For the Pharmaceutical Reimbursement Calculator an uncounted *co‑payment* is a *co‑payment* for a *Pharmaceutical benefit* where the *co‑payment* is not counted for the purposes of the *safety net* applying to the person.

Note: included here are co‑payments for *Pharmaceutical benefits* dispensed under the “Safety Net 20 Day Rule” (subsection 84C(4AA)) of the *National Health Act 1953*.

Part 5B—Under Co‑payment Data Collection

40A Giving information

 (1) A *Community Pharmacist* who gives information to the *Secretary* in relation to the supply, under the *Scheme*, of a *Pharmaceutical benefit* by the pharmacist to an *Eligible Person*, is taken to have given that information under, and for the purposes of, the *Scheme*, provided that:

 (a) no claim for payment is made by the *Community Pharmacist* on the *Commission* or *Department* for dispensing the *Pharmaceutical benefit*; and

 (b) the dispensing price of the *pharmaceutical benefit* is less than, or equal to, the *co‑payment* that would have been paid by the *Eligible Person* for the *pharmaceutical benefit* if it had been dispensed at a price for which a *co‑payment* is payable; and

 (c) the information is given in accordance with the requirements, to the extent applicable, that apply under section 98AC of the *National Health Act 1953* to an *approved supplier* giving information to the *Secretary* in relation to the supply to a person of a pharmaceutical benefit, as if references in section 98AC to an *approved supplier* and a pharmaceutical benefit are references to, respectively, a *Community Pharmacist* and a *Pharmaceutical benefit* and the pharmaceutical benefit has been supplied under the *Scheme*.

Note: a Community Pharmacist includes an Approved Hospital Authority.

Part 6—Miscellaneous

41 Standards

 The minimum acceptable standard for a *Pharmaceutical benefit* is that described in the regulations under the *Therapeutic Goods Act 1989* which relate to specific standards for drugs.

45 Keeping documents‑other than for continued dispensing or medication chart prescriptions

 (1) If a *Community Pharmacist* supplies a *Pharmaceutical benefit*, other than a *Pharmaceutical benefit* that is:

 (a) a dangerous drug (defined below); or

 (b) supplied under section 16A (continued dispensing); or

 (c) supplied on the basis of a medication chart prescription;

 the *Community Pharmacist* must keep a document specified in subsection (2) that relates to the supply for at least 2 years after the supply.

 (2) For subsection (1), the following documents are specified:

 (a) in the case of supply upon a prescription not bearing instructions to supply the *Pharmaceutical benefit* more than once:

 (i) for a paper‑based prescription—the pharmacist/patient copy and the Medicare Australia/DVA copy; or

 (ii) for an electronic prescription—the electronic prescription, or a copy of the electronic prescription;

 (ab) in the case of supply upon a prescription bearing instructions to supply the Pharmaceutical benefit more than once, if it is supplied on the first occasion on which supply is authorised:

 (i) for a paper‑based prescription—the Medicare Australia/DVA copy ; or

 (ii) for an electronic prescription—the electronic prescription, or a copy of the electronic prescription and the repeat authorisation;

 (ac) in the case of supply upon a prescription bearing instructions to supply the Pharmaceutical benefit more than once, if it is supplied other than on the first or last occasion on which supply is authorised:

 (i) for a paper‑based prescription—the repeat authorisation for the most recent previous supply; or

 (ii) for an electronic prescription—the electronic prescription, or a copy of the electronic prescription and the repeat authorisation for the most recent previous supply;

 (b) in the case of supply upon a prescription bearing instructions to supply the Pharmaceutical benefit more than once, if it is supplied on the last occasion on which supply is authorised:

 (i) for a paper‑based prescription—the pharmacist/patient copy and the repeat authorisation for the most recent previous supply; or

 (ii) for an electronic prescription—the electronic prescription, or a copy of the electronic prescription and the repeat authorisation for the most recent previous supply;

Note: The document may be kept in an electronic form (see subsection 12(2) of the *Electronic Transactions Act 1999)*.

 (3) In this section:

***dangerous drug*** means a drug or medicinal preparation in respect of which the law of the State or Territory in which the prescription is written provides that a pharmacist who dispenses that drug or medicinal preparation, or who dispenses it on the last of a number of occasions of supply indicated in a prescription for its supply, must take possession of the prescription and cancel it or deliver it to the authority administering that law.

45A Keeping documents—continued dispensing

 (1) If a Community Pharmacist supplies a Pharmaceutical benefit to a person under section 16A (continued dispensing), the pharmacist is to keep the following information for at least 2 years from the date on which the Pharmaceutical benefit was supplied by the Community Pharmacist:

 (a) the information that supports the claim for payment made under section 24 (in effect, under section 99AAA of the *National Health Act 1953*) in relation to the supply of the Pharmaceutical benefit including the repeat authorisation form;

 (b) the information, about the supply of the Pharmaceutical benefit, that is given to the *RPBS prescriber* who most recently prescribed the Pharmaceutical benefit to the person.

Note: The document may be kept in an electronic form (see subsection 12(2) of the *Electronic Transactions Act 1999*).

45B Keeping documents—medication chart prescriptions

(1) If a Community Pharmacist supplies a Pharmaceutical benefit on the basis of a medication chart prescription, the pharmacist is to keep the medication chart, or a copy of the medication chart on which the Community Pharmacist wrote the details mentioned in paragraph 16AA(2)(c) in relation to the prescription, for at least 2 years from the date of supply.

Note: The document may be kept in an electronic form (see subsection 12(2) of the *Electronic Transactions Act 1999)*.

46 Agreement with the Pharmacy Guild of Australia

 The *Commission* may enter into agreements concerning the administration of this Part with The Pharmacy Guild of Australia and, subject to this Part, shall abide by such agreements.

47 Transitional provision relating to the Veterans’ Affairs Pharmaceutical Benefits Schemes (Electronic Prescriptions and Active Ingredient Prescribing) Amendment Instrument 2019

 (1) This section applies in relation to a prescription for the supply of a *Pharmaceutical benefit* that is written before 1 February 2021.

 (2) Despite the amendments of section 11A of the *Repatriation Pharmaceutical Benefits Scheme* made by Part 2 of Schedule 1 to the *Veterans’ Affairs Pharmaceutical Benefits Schemes (Electronic Prescriptions and Active Ingredient Prescribing) Amendment Instrument 2019*, a prescription that is not a *medication chart prescription* is taken to have been written in accordance with section 11A if the prescription is written in accordance with that section as in force immediately before 31 October 2019.

 (3) Despite the amendments of section 11B of the *Repatriation Pharmaceutical Benefits Scheme* made by Part 2 of Schedule 1 to the *Veterans’ Affairs Pharmaceutical Benefits Schemes (Electronic Prescriptions and Active Ingredient Prescribing) Amendment Instrument 2019*, a prescription that is a *medication chart prescription* is taken to have been written in accordance with section 11B if the prescription is written in accordance with that section as in force immediately before 31 October 2019.

SCHEDULE 1 — INCORPORATED DOCUMENTS

The following documents are incorporated by reference into the *Scheme* in the form in which they exist from time to time:

         *Eighth Community Pharmacy Agreement*

 https://www.health.gov.au/resources/publications/eighth‑community‑pharmacy‑agreement

         *Explanatory Notes*

 http://www.pbs.gov.au/info/healthpro/explanatory‑notes

         *RPBS Explanatory Notes*

 https://www.pbs.gov.au/info/browse/rpbs/rpbs‑explanatorynotes

         *PBS or Pharmaceutical Benefits Scheme*

 http://www.pbs.gov.au/browse/publications

         *RPBS Schedule*

 http://www.pbs.gov.au/browse/rpbs

 Note: “RPBS Schedule” is defined to mean the Repatriation Schedule of

 Pharmaceutical Benefits which is further defined.

Schedule 2—Pharmaceutical benefits not covered by PBS—continued dispensing

Note: See paragraph 16A(1A)(a).

| Pharmaceutical benefits not covered by the PBS—continued dispensing |
| --- |
| Column 1**Sequence** | Column 2RPBS item code | Column 3Name | Column 4Form |
| 1  |  1905G  | Dressing-alginate (cavity wound) | Rope 2 g |
| 2  |  2191H  | Risedronic acid | Tablet (enteric coated) containing risedronate sodium 35 mg |
| 3  |  2194L  | Alendronic acid with colecalciferol | Tablet 70 mg (as alendronate sodium) with 70 micrograms colecalciferol |
| 4  |  2224C  | Alendronic acid with colecalciferol | Tablet 70 mg (as alendronate sodium) with 140 micrograms colecalciferol |
| 5  |  2439J  | Dressing-foam with silver and silicone | Dressings 10 cm x 10 cm, 5 |
| 6  |  2445Q  | Dressing-gelling fibre | Dressings, non-woven, gelling fibre 15 cm x 15 cm, 5 |
| 7  |  2462N  | Dressing-gelling fibre | Dressings, non-woven, gelling fibre 2 cm x 45 cm rope, 5 |
| 8  |  2470B  | Dressing-foam with silver and silicone | Dressings, border, 10 cm x 10 cm, 5 |
| 9  |  2471C  | Dressing-hydrogel | Dressing 10 cm x 10 cm |
| 10  |  2486W  | Dressing-gelling fibre | Dressings, non-woven, gelling fibre 10 cm x 10 cm, 10 |
| 11  |  2512F  | Dressing-antimicrobial-ribbon | Dressing 1 cm x 50 cm |
| 12  |  2525X  | Wound irrigation solution | Solution containing betaine 0.1% with polihexanide 0.1%, 40 mL ampoule, 6 |
| 13  |  2529D  | Dressing-antimicrobial-ribbon | Dressing 5 cm x 200 cm |
| 14  |  2533H  | Dressing-antimicrobial-foam | Dressing 10 cm x 10 cm |
| 15  |  2797F  | Dressing-hydrofibre (alternate to alginates) | Dressings 10 cm x 10 cm, 10 |
| 16  |  2803M  | Dressing-hydrofibre (alternate to alginates) | Dressings 15 cm x 15 cm, 5 |
| 17  |  4004R  | Clotrimazole | Cream 10 mg per g, 20 g |
| 18  |  4010C  | Amorolfine hydrochloride | Nail treatment kit containing nail lacquer 50 mg (base) per mL (5%), 5 mL, 60 isopropyl alcohol cleaning pads, 10 spatulas and 30 nail files |
| 19  |  4011D  | Terbinafine | Tablet 250 mg (as hydrochloride) |
| 20  |  4013F  | Nystatin | Vaginal cream 100,000 units per dose, 15 doses, 75 g |
| 21  |  4016J  | Clotrimazole | Vaginal cream 50 mg per 5 g (1%), 35 g |
| 22  |  4017K  | Clotrimazole | Vaginal cream 100 mg per 5 g (2%), 20 g |
| 23  |  4029C  | Pseudoephedrine hydrochloride | Tablet 60 mg |
| 24  |  4039N  | Zinc oxide | Compound ointment 50 g |
| 25  |  4040P  | Zinc oxide | Compound suppositories, 12 |
| 26  |  4041Q  | Wool alcohols | Ointment 100 g |
| 27  |  4042R  | Urea | Cream 100 mg per g (10%), 100 g |
| 28  |  4043T  | Thiamine | Tablet containing thiamine hydrochloride 100 mg |
| 29  |  4046Y  | Diclofenac | Gel containing diclofenac sodium 30 mg per g, 25 g |
| 30  |  4049D  | Sodium citro-tartrate | Sachets containing oral effervescent powder 4 g, 28 |
| 31  |  4050E  | Bandage-compression | Bandage, two layer |
| 32  |  4070F  | Tamsulosin hydrochloride | Tablet 400 micrograms (prolonged release) |
| 33  |  4076M  | Aspirin | Tablet 100 mg (with glycine) |
| 34  |  4077N  | Aspirin | Tablet 100 mg (enteric coated) |
| 35  |  4078P  | Aspirin | Capsule 100 mg (containing enteric coated pellets) |
| 36  |  4082W  | Calcium | Tablet 600 mg (as carbonate) |
| 37  |  4092J  | Budesonide | Aqueous nasal spray (pump pack) 64 micrograms per dose (120 doses) |
| 38  |  4107E  | Skin emollient | Lotion 500 mL |
| 39  |  4115N  | Azithromycin | Tablet 500 mg (as dihydrate) |
| 40  |  4122Y  | Skin emollient | Bath oil 500 mL |
| 41  |  4131K  | Betamethasone | Cream 1 mg (as valerate) per g, 30 g |
| 42  |  4132L  | Betamethasone | Ointment 1 mg (as valerate) per g, 30 g |
| 43  |  4134N  | Imiquimod | Cream 50 mg per g, 250 mg single use sachets, 12 |
| 44  |  4142B  | Calcium | Tablet 600 mg (as carbonate) |
| 45  |  4150K  | Bromazepam | Tablet 3 mg |
| 46  |  4151L  | Bromazepam | Tablet 6 mg |
| 47  |  4161B  | Chlorhexidine gluconate | Mouth wash 2 mg per mL (0.2%), 250 mL |
| 48  |  4175R  | Cetirizine hydrochloride | Tablet 10 mg |
| 49  |  4176T  | Carbamide peroxide | Ear drops 65 mg per mL (6.5%), 12 mL |
| 50  |  4179Y  | Clopidogrel | Tablet 75 mg (as hydrogen sulfate) |
| 51  |  4180B  | Dichlorobenzene with chlorobutanol and arachis oil | Ear drops, ortho-dichlorobenzene 140 mg per mL, para-dichlorobenzene 20 mg per mL, chlorobutanol hemihydrate 50 mg per mL, arachis oil 573 mg per mL, 10 mL |
| 52  |  4196W  | Dressing-foam with silicone-heavy exudate | Dressings 10 cm x 10 cm, 10 |
| 53  |  4199B  | Docusate sodium | Ear drops 5 mg per mL (0.5%), 10 mL |
| 54  |  4200C  | Docusate sodium | Tablet 50 mg |
| 55  |  4204G  | Chlorhexidine gluconate | Mouth wash 2 mg per mL (0.2%), 300 mL |
| 56  |  4207K  | Dressing-foam with silicone-heavy exudate | Dressings 7.5 cm x 7.5 cm, 10 |
| 57  |  4216X  | Flunitrazepam | Tablet 1 mg |
| 58  |  4222F  | Fluorouracil | Cream 50 mg per g (5%), 20 g |
| 59  |  4230P  | Dressing-foam with silicone-heavy exudate | Dressings 10 cm x 10 cm, 10 |
| 60  |  4233T  | Finasteride | Tablet 5 mg |
| 61  |  4237B  | Fexofenadine hydrochloride | Tablet 60 mg |
| 62  |  4238C  | Fexofenadine hydrochloride | Tablet 120 mg |
| 63  |  4239D  | Tapes-plaster adhesive (with silicone) | Roll 2 cm x 3 m |
| 64  |  4240E  | Tapes-plaster adhesive (with silicone) | Roll 4 cm x 1.5 m |
| 65  |  4243H  | Dressing-non-adherent | Dressings, non-woven, with silicone 5 cm x 7.5 cm, 10 |
| 66  |  4244J  | Dressing-non-adherent | Dressings, non-woven, with silicone 7.5 cm x 10 cm, 10 |
| 67  |  4246L  | Glycerol | Suppositories 2.8 g, 12 |
| 68  |  4252T  | Dressing-foam-silver | Dressings, adhesive, 7.5 cm x 7.5 cm, 10 |
| 69  |  4255Y  | Dressing-foam-silver | Dressings, adhesive, 10 cm x 10 cm, 10 |
| 70  |  4258D  | Dressing-foam-silver | Dressings, adhesive, 12.5 cm x 12.5 cm, 10 |
| 71  |  4259E  | Dressing-foam-silver | Dressings, non-adhesive, 10 cm x 10 cm, 10 |
| 72  |  4263J  | Dressing-foam-silver | Dressings 7.5 cm x 7.5 cm, 10 |
| 73  |  4266M  | Dressing-foam-silver | Dressings 10 cm x 10 cm, 10 |
| 74  |  4270R  | Dressing-foam-silver | Dressings 12.5 cm x 12.5 cm, 10 |
| 75  |  4275B  | Codeine with paracetamol | Tablet containing codeine phosphate hemihydrate 8 mg with paracetamol 500 mg |
| 76  |  4277D  | Alfuzosin hydrochloride | Tablet 10 mg |
| 77  |  4279F  | Hyoscine | Injection containing hyoscine butylbromide 20 mg in 1 mL |
| 78  |  4280G  | Ichthammol with zinc oxide | Ointment 10 mg-150 mg per g (1%-15%), 50 g |
| 79  |  4281H  | Ichthammol | Cream 10 mg per g (1%), 50 g |
| 80  |  4284L  | Infliximab | Powder for I.V. infusion 100 mg |
| 81  |  4285M  | Ispaghula husk | Sachets 3.5 g, 30 |
| 82  |  4286N  | Codeine with aspirin | Tablet containing codeine phosphate hemihydrate 8 mg with aspirin 300 mg |
| 83  |  4303L  | Finasteride | Tablet 5 mg |
| 84  |  4306P  | Lubricating gel | Tube 100 g |
| 85  |  4307Q  | Sunscreens | Cream 75 g |
| 86  |  4308R  | Lidocaine | Solution containing lidocaine hydrochloride 20 mg per mL (2%), 200 mL |
| 87  |  4313B  | Loratadine | Tablet 10 mg |
| 88  |  4321K  | Magnesium | Tablet 37.4 mg (as aspartate dihydrate) |
| 89  |  4325P  | Mebendazole | Tablet 100 mg |
| 90  |  4328T  | Mebeverine hydrochloride | Tablet 135 mg |
| 91  |  4342M  | Mometasone | Cream containing mometasone furoate 1 mg per g, 50 g |
| 92  |  4343N  | Mometasone | Ointment containing mometasone furoate 1 mg per g, 50 g |
| 93  |  4348W  | Mupirocin | Cream 20 mg (as calcium) per g, 15 g |
| 94  |  4349X  | Morphine | Tablet containing morphine sulfate pentahydrate 200 mg (controlled release) |
| 95  |  4350Y  | Mupirocin | Ointment 20 mg per g, 15 g |
| 96  |  4378K  | Oxymetazoline hydrochloride | Nasal spray 500 micrograms per mL (0.05%), 15 mL |
| 97  |  4379L  | Oxymetazoline hydrochloride | Nasal spray 500 micrograms per mL (0.05%), 18 mL |
| 98  |  4408B  | Pine tar with trolamine lauril sulfate | Solution 23 mg-60 mg per mL (2.3%-6%), 500 mL |
| 99  |  4411E  | Povidone-Iodine | Solution 100 mg per mL (10%), 100 mL |
| 100  |  4419N  | Psyllium hydrophilic mucilloid | Oral powder (orange-flavoured, sugar-free) 283 g |
| 101  |  4434J  | Ricinoleic acid with acetic acid and oxyquinoline sulfate | Vaginal jelly 7.5 mg-9.4 mg-250 micrograms per g (0.75%-0.94%-0.025%), 100 g |
| 102  |  4443W  | Risedronic acid | Tablet containing risedronate sodium 5 mg |
| 103  |  4444X  | Risedronic acid | Tablet containing risedronate sodium 35 mg |
| 104  |  4447C  | Salicylic acid with coal tar solution and pine tar | Scalp cleanser 20 mg-10 mg-10 mg per mL (2%-1%-1%), 250 mL |
| 105  |  4452H  | Selenium sulfide | Shampoo 25 mg per mL (2.5%), 125 mL |
| 106  |  4455L  | Senna standardised | Tablet 7.5 mg |
| 107  |  4460R  | Sodium chloride | Irrigation solution 9 mg per mL (0.9%), 500 mL |
| 108  |  4461T  | Sodium chloride | Irrigation solution 9 mg per mL (0.9%), 1 L |
| 109  |  4462W  | Sorbitol with sodium citrate dihydrate and sodium lauryl sulfoacetate | Enemas 3.125 g-450 mg-45 mg in 5 mL, 4 |
| 110  |  4463X  | Terbinafine | Gel 10 mg per g (1%), 15 g |
| 111  |  4468E  | Cromoglycic acid | Nasal spray metered dose pump containing sodium cromoglycate 20 mg per mL, 26 mL |
| 112  |  4470G  | Sodium polystyrene sulfonate | Oral powder 454 g |
| 113  |  4473K  | Terbinafine | Cream containing terbinafine hydrochloride 10 mg per g, 15 g |
| 114  |  4481W  | Tolnaftate | Spray aerosol 0.7 mg per g (0.07%), 100 g |
| 115  |  4493L  | Vitamin b group complex | Oral liquid 200 mL |
| 116  |  4497Q  | Zinc oxide with starch and chlorphenesin | Dusting powder 100 g |
| 117  |  4505D  | Allantoin with sulfur, phenol, coal tar solution and menthol | Gel 25 mg-5 mg-5 mg-0.05 mL-7.5 mg per g (2.5%-0.5%-0.5%-5%-0.75%), 30 g |
| 118  |  4510J  | Cationic conditioner with panthenol | Cream 200 g |
| 119  |  4518T  | Carmellose sodium with pectin and gelatin | Paste 167 mg-167 mg-167 mg per g (16.7%-16.7%- 16.7%), 5 g |
| 120  |  4522B  | Zopiclone | Tablet 7.5 mg |
| 121  |  4546G  | Sunscreens | Lotion (non-alcoholic) 125 mL |
| 122  |  4549K  | Skin cleanser | Lotion 500 mL |
| 123  |  4559Y  | Imiquimod | Cream 50 mg per g, 250 mg single use sachets, 12 |
| 124  |  4560B  | Salicylic acid with coal tar solution | Scalp cleanser 20 mg-50 mg per mL (2%-5%), 200 mL |
| 125  |  4570M  | Orlistat | Capsule 120 mg |
| 126  |  4571N  | Nicotine | Transdermal patches releasing approximately 7 mg per 24 hours, 7 |
| 127  |  4572P  | Nicotine | Transdermal patches releasing approximately 14 mg per 24 hours, 7 |
| 128  |  4573Q  | Nicotine | Transdermal patches releasing approximately 21 mg per 24 hours, 7 |
| 129  |  4579B  | Alprostadil | Intracavernosal injection 10 micrograms with diluent in single use syringe |
| 130  |  4580C  | Alprostadil | Intracavernosal injection 20 micrograms with diluent in single use syringe |
| 131  |  4584G  | Sildenafil | Tablet 25 mg (as citrate) |
| 132  |  4585H  | Sildenafil | Tablet 50 mg (as citrate) |
| 133  |  4586J  | Sildenafil | Tablet 100 mg (as citrate) |
| 134  |  4590N  | Dressing-foam-moderate exudate | Dressings 12.5 cm x 12.5 cm, 10 |
| 135  |  4591P  | Gabapentin | Capsule 100 mg |
| 136  |  4592Q  | Gabapentin | Capsule 300 mg |
| 137  |  4593R  | Gabapentin | Capsule 400 mg |
| 138  |  4594T  | Gabapentin | Tablet 600 mg |
| 139  |  4595W  | Gabapentin | Tablet 800 mg |
| 140  |  4596X  | Tadalafil | Tablet 10 mg |
| 141  |  4597Y  | Tadalafil | Tablet 20 mg |
| 142  |  4598B  | Bandage-compression | Bandage, four layer |
| 143  |  4599C  | Dressing-hydrogel-amorphous | Tube 50 g |
| 144  |  4626L  | Dressing-foam with silicone-moderate exudate | Dressings 10 cm x 10 cm, 5 |
| 145  |  4644K  | Dressing-foam with silicone-light exudate | Dressings 6 cm x 8.5 cm, 5 |
| 146  |  4645L  | Dressing-foam with silicone-light exudate | Dressings 10 cm x 10 cm, 5 |
| 147  |  4646M  | Dressing with silver | Hydroactive dressings non-adhesive 10 cm x 10 cm, 5 |
| 148  |  4647N  | Dressing with silver | Hydroactive dressings adhesive 12.5 cm x 12.5 cm, 5 |
| 149  |  4648P  | Dressing with silver | Tulle dressings 10 cm x 10 cm, 3 |
| 150  |  4653X  | Bandage-absorbent wool | Bandage 10 cm x 3 m |
| 151  |  4654Y  | Bandage-compression | Bandage, short stretch, 8 cm x 2.6 m |
| 152  |  4657D  | Bandage-compression | Bandage, high stretch, 10 cm x 3.5 m |
| 153  |  4658E  | Bandage-compression | Bandage, four layer |
| 154  |  4660G  | Bandage-retention-cohesive-heavy | Bandage 10 cm x 2 m |
| 155  |  4661H  | Bandage-tubular (short stocking) | Bandage, small B/C size |
| 156  |  4662J  | Bandage-retention-cohesive-light | Bandage 10 cm x 4 m |
| 157  |  4663K  | Bandage-tubular | Bandage, straight, size C |
| 158  |  4664L  | Bandage-tubular | Bandage, straight, size D |
| 159  |  4665M  | Bandage-tubular | Bandage, straight, size E |
| 160  |  4669R  | Bandage-zinc paste | Bandage 7.5 cm x 6 m |
| 161  |  4671W  | Bandage-tubular (lightweight) | Bandage, small limb size (red), 10 m |
| 162  |  4672X  | Bandage-tubular (lightweight) | Bandage, medium limb size (green), 10 m |
| 163  |  4673Y  | Bandage-tubular (lightweight) | Bandage, large limb size (blue), 10 m |
| 164  |  4674B  | Bandage-tubular (long stocking) | Bandage, small size |
| 165  |  4675C  | Bandage-tubular (long stocking) | Bandage, XX/large size |
| 166  |  4678F  | Dressing-hydrocolloid (superficial wound-moderate exudate) | Butterfly shape 7 cm |
| 167  |  4679G  | Dressing-hydrocolloid (superficial wound-moderate exudate) | Round 10 cm |
| 168  |  4681J  | Dressing-activated charcoal (malodorous wound) | Dressing 10.5 cm x 10.5 cm |
| 169  |  4682K  | Dressing-alginate (cavity wound) | Ropes 2 g (40 cm), 6 |
| 170  |  4683L  | Dressing-alginate (superficial wound) | Dressings 7.5 cm x 12 cm, 10 |
| 171  |  4684M  | Dressing-alginate (superficial wound) | Dressing (5 cm x 5 cm) |
| 172  |  4686P  | Dressing-film | Dressings 6 cm x 7 cm, 8 |
| 173  |  4687Q  | Dressing-film | Dressings 10 cm x 12 cm, 4 |
| 174  |  4688R  | Dressing-film | Dressing 15 cm x 20 cm |
| 175  |  4689T  | Dressing-film island | Dressing 5 cm x 7 cm |
| 176  |  4690W  | Dressing-film island | Dressing 9 cm x 10 cm |
| 177  |  4691X  | Dressing-alginate (superficial wound) | Dressings 15 cm x 20 cm, 10 |
| 178  |  4694C  | Dressing-foam-moderate exudate | Dressing, cavity, conforming, 20 g |
| 179  |  4695D  | Dressing-hydroactive (superficial wound-high exudate) | Dressings, island, 11 cm x 11 cm, 10 |
| 180  |  4696E  | Dressing-hydroactive (superficial wound-high exudate) | Dressings, island, 18 cm x 18 cm, 5 |
| 181  |  4698G  | Dressing-hydrofibre (alternate to alginates) | Ribbons 2 cm x 45 cm, 5 |
| 182  |  4699H  | Dressing-alginate (superficial wound) | Dressings 5 cm x 5 cm, 10 |
| 183  |  4700J  | Dressing-alginate (superficial wound) | Dressings 10 cm x 10 cm, 10 |
| 184  |  4707R  | Dressing-gauze (absorbent pad) | Pads 5 cm x 5 cm, 100 |
| 185  |  4708T  | Dressing-gauze (absorbent pad) | Pads 10 cm x 10 cm, 100 |
| 186  |  4717G  | Bandage-calico | Bandage, triangular, large |
| 187  |  4718H  | Bandage-retention-cohesive-light | Bandages 2.5 cm x 4 m, 2 |
| 188  |  4719J  | Bandage-retention-cohesive-light | Bandage 6 cm x 4 m |
| 189  |  4727T  | Bandage-retention-cotton crepe | Bandage 5 cm x 2.3 m |
| 190  |  4728W  | Bandage-retention-cotton crepe | Bandage 7.5 cm x 2.3 m |
| 191  |  4729X  | Bandage-retention-cotton crepe | Bandage 10 cm x 2.3 m |
| 192  |  4742N  | Dressing-activated charcoal (malodorous wound) | Dressings 10 cm x 10 cm, 10 |
| 193  |  4743P  | Dressing-activated charcoal (malodorous wound) | Dressings 15 cm x 20 cm, 5 |
| 194  |  4748X  | Bandage-compression | Bandage, high stretch, 10 cm x 3 m |
| 195  |  4750B  | Bandage-zinc paste | Bandage 7.5 cm x 6 m |
| 196  |  4759L  | Dressing-gauze-paraffin | Dressings 10 cm x 10 cm, 10 |
| 197  |  4760M  | Bandage-zinc paste | Bandages 80 cm (stockings), 4 |
| 198  |  4761N  | Gauze and cotton tissue (combine roll) | Wrapped pack 10 cm x 10 m |
| 199  |  4767X  | Gauze and cotton tissue (combine roll) | Wrapped pack 9 cm x 10 m |
| 200  |  4768Y  | Dressing-gauze-eye pad | Pads, 12 |
| 201  |  4780N  | Tapes-plaster adhesive elastic | Roll 2.5 cm x 2.5 m |
| 202  |  4781P  | Tapes-plaster adhesive elastic | Roll 5 cm x 2.5 m |
| 203  |  4782Q  | Tapes-plaster adhesive elastic | Roll 7.5 cm x 2.5 m |
| 204  |  4783R  | Tapes-plaster adhesive hypoallergenic | Roll 1.25 cm x 5 m |
| 205  |  4785W  | Tapes-plaster adhesive hypoallergenic | Roll 1.25 cm x 5 m |
| 206  |  4787Y  | Tapes-plaster adhesive hypoallergenic | Roll 2.5 cm x 5 m |
| 207  |  4788B  | Tapes-plaster adhesive hypoallergenic | Stretch roll 5 cm x 5 m |
| 208  |  4789C  | Tapes-plaster adhesive hypoallergenic | Roll 5 cm x 5 m |
| 209  |  4790D  | Tapes-plaster adhesive hypoallergenic | Roll 5 cm x 5 m |
| 210  |  4794H  | Tapes-plaster adhesive hypoallergenic | Roll 2.5 cm x 5 m |
| 211  |  4795J  | Dressing-foam-heavy exudate | Dressings 10 cm x 10 cm, 10 |
| 212  |  4797L  | Bandage-tubular (long stocking) | Bandage, medium size |
| 213  |  4798M  | Bandage-tubular (finger) | Complete pack including applicator |
| 214  |  4799N  | Bandage-tubular (long stocking) | Bandage, large size |
| 215  |  4806Y  | Dressing-hydrogel-sheet | Dressings 10 cm x 10 cm, 5 |
| 216  |  4811F  | Bandage-retention-cohesive-heavy | Bandage 5 cm x 1.3 m |
| 217  |  4812G  | Bandage-retention-cohesive-heavy | Bandage 7.5 cm x 1.3 m |
| 218  |  4813H  | Bandage-retention-cohesive-heavy | Bandage 10 cm x 1.3 m |
| 219  |  4814J  | Bandage-retention-cohesive-heavy | Bandage 15 cm x 1.3 m |
| 220  |  4815K  | Bandage-tubular (short stocking) | Bandage, medium C/D size |
| 221  |  4816L  | Bandage-tubular (short stocking) | Bandage, large D/E size |
| 222  |  4819P  | Dressing-non-adherent | Dressings 5 cm x 5 cm, 5 |
| 223  |  4831G  | Dressing-alginate (superficial wound) | Dressing 10 cm x 10 cm |
| 224  |  4832H  | Dressing-alginate (cavity wound) | Rope 2 g |
| 225  |  4845B  | Dressing-gauze-paraffin with chlorhexidine acetate | Dressings 10 cm x 10 cm, 10 |
| 226  |  4848E  | Tapes-plaster adhesive hypoallergenic | Roll (dispenser) 1.9 cm x 5.4 m |
| 227  |  4849F  | Tapes-plaster adhesive hypoallergenic | Roll (dispenser) 1.9 cm x 7.3 m |
| 228  |  4855M  | Bandage-tubular | Bandage 6.25 cm x 1 m |
| 229  |  4856N  | Bandage-tubular | Bandage 6.75 cm x 1 m |
| 230  |  4857P  | Bandage-tubular | Bandage 7.5 cm x 1 m |
| 231  |  4858Q  | Bandage-tubular | Bandage 8.75 cm x 1 m |
| 232  |  4859R  | Bandage-tubular | Bandage 10 cm x 1 m |
| 233  |  4860T  | Dressing-non-adherent | Dressings 5 cm x 5 cm, 5 |
| 234  |  4861W  | Dressing-non-adherent | Dressings 10 cm x 10 cm, 10 |
| 235  |  4862X  | Dressing-non-adherent | Dressings 10 cm x 10 cm, 5 |
| 236  |  4885D  | Dressing-hydroactive (superficial wound-moderate exudate) | Dressings 5 cm x 6 cm, 10 |
| 237  |  4886E  | Dressing-hydroactive (superficial wound-moderate exudate) | Dressings 10 cm x 10 cm, 5 |
| 238  |  4888G  | Dressing-hydrocolloid (superficial wound-light exudate) | Dressings 5 cm x 7 cm, 10 |
| 239  |  4889H  | Dressing-hydrocolloid (superficial wound-light exudate) | Dressings 9 cm x 14 cm, 10 |
| 240  |  4893M  | Dressing-film | Dressings 10 cm x 12 cm, 10 |
| 241  |  4894N  | Dressing-hydrogel-amorphous | Tube 25 g |
| 242  |  4896Q  | Dressing-hydrocolloid (cavity wound) | Paste 30 g |
| 243  |  4897R  | Dressing-hydrocolloid (superficial wound-moderate exudate) | Dressings (10 cm x 10 cm), 5 |
| 244  |  4898T  | Dressing-film island | Dressings 5 cm x 7.2 cm, 5 |
| 245  |  4899W  | Dressing-film island | Dressings 8 cm x 10 cm, 5 |
| 246  |  4905E  | Dressing-hydroactive (superficial wound-light exudate) | Dressings 5 cm x 6 cm, 10 |
| 247  |  4906F  | Dressing-hydroactive (superficial wound-light exudate) | Dressings 10 cm x 10 cm, 5 |
| 248  |  4907G  | Dressing-hydrocolloid (superficial wound-light exudate) | Dressings 10 cm x 10 cm, 10 |
| 249  |  4909J  | Dressing-tulle non-adherent-paraffin | Dressing 7.6 cm x 7.6 cm |
| 250  |  4911L  | Dressing-hydrogel-sheet | Dressings 9.5 cm x 10.2 cm, 5 |
| 251  |  4912M  | Dressing-hydrogel-amorphous | Tubes 15 g, 10 |
| 252  |  4913N  | Dressing-hydrogel-amorphous | Tubes 30 g, 3 |
| 253  |  4914P  | Dressing-hydrogel-amorphous | Tube 50 g |
| 254  |  4915Q  | Tapes-non-woven retention (polyacrylate) | Roll 2.5 cm x 9.1 m |
| 255  |  4917T  | Tapes-non-woven retention (polyacrylate) | Roll 2.5 cm x 10 m |
| 256  |  4920Y  | Dressing-hydrocolloid (superficial wound-moderate exudate) | Dressings 20 cm x 20 cm, 5 |
| 257  |  4921B  | Dressing-hydrocolloid (superficial wound-moderate exudate) | Dressings 10 cm x 10 cm, 10 |
| 258  |  4923D  | Dressing-hydrocolloid (superficial wound-moderate exudate) | Dressings with alginate 10 cm x 10 cm, 10 |
| 259  |  4924E  | Dressing-hydrocolloid (superficial wound-light exudate) | Dressings 10 cm x 10 cm, 10 |
| 260  |  4927H  | Dressing-hydroactive (superficial wound-high exudate) | Non-adhesive waterproof semi-permeable absorbent foam pads 10 cm x 10 cm, 10 |
| 261  |  4928J  | Dressing-hydroactive (superficial wound-high exudate) | Non-adhesive waterproof semi-permeable absorbent foam pads 15 cm x 15 cm, 5 |
| 262  |  4929K  | Dressing-hydroactive (superficial wound-high exudate) | Adhesive waterproof semi-permeable absorbent foam pads 12 cm x 12 cm, 10 |
| 263  |  4930L  | Dressing-hydroactive (superficial wound-high exudate) | Adhesive waterproof semi-permeable absorbent foam pads 18 cm x 18 cm, 5 |
| 264  |  4931M  | Dressing with cadexomer iodine | Sachets 3 g, 7 |
| 265  |  4932N  | Dressing with cadexomer iodine | Tubes 10 g, 4 |
| 266  |  4933P  | Dressing with cadexomer iodine | Tubes 20 g, 2 |
| 267  |  4935R  | Dressing with cadexomer iodine | Sheets 5 g (6 cm x 4 cm), 5 |
| 268  |  4936T  | Dressing with cadexomer iodine | Sachets 10 g (8 cm x 6 cm), 3 |
| 269  |  4937W  | Dressing with cadexomer iodine | Sheets 17 g (10 cm x 8 cm), 2 |
| 270  |  4944F  | Dressing-non-adherent | Dressings 7.5 cm x 10 cm, 10 |
| 271  |  4945G  | Dressing-hydrocolloid (superficial wound-moderate exudate) | Dressings 10 cm x 10 cm, 10 |
| 272  |  4946H  | Dressing-hydrocolloid (superficial wound-moderate exudate) | Dressings 15 cm x 15 cm, 10 |
| 273  |  4947J  | Dressing-hydrocolloid (superficial wound-light exudate) | Dressings 10 cm x 10 cm, 10 |
| 274  |  4948K  | Dressing-hydroactive (debridement) | Dressings 5.5 cm, 10 |
| 275  |  4949L  | Dressing-hydroactive (debridement) | Dressings 4 cm, 10 |
| 276  |  4950M  | Dressing-hydroactive (debridement) | Dressings 7.5 cm x 7.5 cm, 10 |
| 277  |  10017F  | Dressing-foam with silicone | Dressings 10.3 cm x 10.3 cm, 10 |
| 278  |  10021K  | Dressing-foam with silicone | Dressings 21 cm x 21 cm, 10 |
| 279  |  10023M  | Dressing-foam with silicone | Dressings 15.4 cm x 15.4 cm, 10 |
| 280  |  10029W  | Dressing-foam with silicone | Dressings 12.9 cm x 12.9 cm, 10 |
| 281  |  10095H  | Dutasteride | Capsule 500 micrograms |
| 282  |  10097K  | Dressing hydrofibre with silver | Dressing 10 cm x 10 cm |
| 283  |  10098L  | Dressing hydrofibre with silver | Dressing 15 cm x 15 cm |
| 284  |  10102Q  | Dutasteride with tamsulosin | Capsule containing dutasteride 500 micrograms with tamsulosin hydrochloride 400 micrograms |
| 285  |  10105W  | Dressing hydrofibre with silver | Ribbon 2 cm x 45 cm |
| 286  |  10106X  | Imiquimod | Cream 50 mg per g, 2 g, 2 |
| 287  |  10169F  | Clopidogrel | Tablet 75 mg (as besilate) |
| 288  |  10177P  | Docusate with sennoside B | Tablet containing docusate sodium 50 mg with sennoside B 8 mg |
| 289  |  10573L  | Folic acid | Tablet 5 mg |
| 290  |  10577Q  | Hydroxocobalamin | Injection 1 mg (as acetate) in 1 mL |
| 291  |  10578R  | Bisacodyl | Suppositories 10 mg, 10 |
| 292  |  10579T  | Ferrous fumarate with folic acid | Tablet 310 mg (equivalent to 100 mg iron)-350 micrograms |
| 293  |  10580W  | Bisacodyl | Suppositories 10 mg, 12 |
| 294  |  10582Y  | Paracetamol | Tablet 500 mg |
| 295  |  10584C  | Folic acid | Tablet 500 micrograms |
| 296  |  10585D  | Paracetamol | Tablet 500 mg |
| 297  |  10586E  | Glycerol | Suppositories 700 mg, 12 |
| 298  |  10587F  | Hydroxocobalamin | Injection 1 mg (as chloride) in 1 mL |
| 299  |  10590J  | Aspirin | Tablet 100 mg |
| 300  |  10592L  | Loperamide | Capsule containing loperamide hydrochloride 2 mg |
| 301  |  10594N  | Ferrous fumarate | Tablet 200 mg (equivalent to 65.7 mg iron) |
| 302  |  10596Q  | Glycerol | Suppositories 1.4 g, 12 |
| 303  |  10598T  | Paracetamol | Tablet 665 mg (modified release) |
| 304  |  10599W  | Paracetamol | Oral liquid 240 mg per 5 mL, 200 mL |
| 305  |  10831C  | Hydrocortisone | Ointment containing hydrocortisone acetate 10 mg per g, 30 g |
| 306  |  10832D  | Dressing-hydrofibre (alternate to alginates) | Dressing 12.5 cm x 12.5 cm |
| 307  |  10837J  | Dressing-hydrofibre (alternate to alginates) | Dressing 10 cm x 10 cm |
| 308  |  10847X  | Povidone-Iodine | Dressing 9.5 cm x 9.5 cm |
| 309  |  10849B  | Dressing alginate with manuka honey | Dressing 10 cm x 10 cm |
| 310  |  10854G  | Nystatin | Oral suspension 100,000 units per mL, 24 mL |
| 311  |  10857K  | Dressing alginate with manuka honey | Ribbon 2.5 cm x 20 cm |
| 312  |  11134B  | Sodium chloride with hypochlorous acid and sodium hypochlorite | Solution containing sodium chloride 0.022% with hypochlorous acid 0.004% and sodium hypochlorite 0.004%, 250 mL |
| 313  |  11135C  | Loperamide | Capsule containing 2 mg loperamide hydrochloride |
| 314  |  11383D  | Pad-wound debridement | Pads 10 cm x 10 cm, 5 |
| 315  |  11384E  | Dressing-foam with silicone | Dressings 10.5 cm x 10.5 cm, 10 |
| 316  |  11391M  | Pad-wound debridement | Pads (with handle), 5 |
| 317  |  11392N  | Dressing-hydrophobic | Dressings (foam gentle border) 10 cm x 10 cm, 10 |
| 318  |  11393P  | Dressing-foam with silicone | Dressings 16 cm x 16 cm, 10 |
| 319  |  11394Q  | Dressing-hydrophobic | Dressings (foam gentle border) 15 cm x 15 cm, 10 |
| 320  |  11395R  | Dressing-hydrogel | Dressings 7.5 cm x 15 cm, 10 |
| 321  |  11401C  | Protein formula with arginine, vitamin C, vitamin E and zinc | Oral liquid 200 mL, 24 (Cubitan) |
| 322  |  11402D  | Dressing-hydrophobic | Dressings (superabsorbent) 10 cm x 10 cm, 10 |
| 323  |  11403E  | Dressing-hydrophobic | Dressings (superabsorbent) 20 cm x 20 cm, 10 |
| 324  |  11404F  | Dressing-hydrophobic | Dressings (foam) 15 cm x 15 cm, 10 |
| 325  |  11707E  | Methyl salicylate with menthol, camphor, eucalyptus oil, pine oil pumilio, turpentine oil, peppermint oil, cajuput oil and capsicum extract | Cream 20%-5%-3.5%-3%-1%-1%-0.5%-0.5%-0.15%, 100 g |
| 326  |  11708F  | Glycerol | Solution 15%, 1 kg |
| 327  |  11709G  | Dressing-hydrogel | Dressings 10 cm x 10 cm, 5 |
| 328  |  11710H  | Hydrocortisone | Cream containing hydrocortisone acetate 10 mg per g, 30 g |
| 329  |  11711J  | Oxymetazoline hydrochloride | Nasal spray 500 micrograms per mL (0.05%), 20 mL |
| 330  |  11712K  | Glycerol with white soft paraffin | Lotion 5%-5%, 1 L |
| 331  |  11714M  | Bandage-compression | Bandage, soft, 10 cm x 3.5 m and bandage, short stretch, 10 cm x 6 m, two component pack |
| 332  |  11715N  | Dressing-non-adherent absorbent | Dressings, hydroactive, 22 cm x 22 cm, 10 |
| 333  |  11717Q  | Dressing-non-adherent absorbent | Dressings, hydroactive, 12.5 cm x 12.5 cm, 10 |
| 334  |  11718R  | Dressing-non-adherent absorbent | Dressings, hydroactive, 22 cm x 32 cm, 10 |
| 335  |  11837B  | Avanafil | Tablet 50 mg |
| 336  |  11845K  | Calcium | Tablet, chewable, 500 mg (as carbonate) |
| 337  |  11860F  | Avanafil | Tablet 200 mg |
| 338  |  11861G  | Avanafil | Tablet 100 mg |
| 339  |  11862H  | Calcium | Tablet, chewable, 500 mg (as carbonate) |
| 340  |  11959K  | Salicylic acid with lactic acid | Liquid 167 mg-150 mg per g (16.7%-15%), 15 mL |
| 341  |  12077P  | Silodosin | Capsule 8 mg |
| 342  |  12079R  | Silodosin | Capsule 4 mg |
| 343  |  12179B  | Sodium citro-tartrate | Sachets containing oral effervescent granules 4 g, 28 |
| 344  |  12181D  | Dressing-gelling fibre | Dressings, non-woven, 10 cm x 10 cm, 10 |
| 345  |  12182E  | Dressing-gelling fibre | Dressings, non-woven, 2 cm x 45 cm, 5 |
| 346  |  12184G  | Dressing-foam with silicone-heavy exudate | Dressings 7.5 cm x 7.5 cm, 10 |
| 347  |  12185H  | Dressing-foam with silicone-heavy exudate | Dressings 15 cm x 20 cm, 10 |
| 348  |  12187K  | Dressing-gelling fibre | Dressings, non-woven, 5 cm x 5 cm, 10 |
| 349  |  12194T  | Mebendazole | Tablet, chewable, 100 mg |
| 350  |  12195W  | Dressing-foam with silicone-heavy exudate | Dressings 22 cm x 23 cm, 6 |
| 351  |  12196X  | Dressing-non-adherent with silicone | Dressings 10 cm x 18 cm, 10 |
| 352  |  12202F  | Dressing-gelling fibre | Dressings, non-woven, 15 cm x 15 cm, 10 |
| 353  |  12206K  | Dressing-foam with silicone-heavy exudate | Dressings 10 cm x 10 cm, 10 |
| 354  |  12207L  | Dressing-foam with silicone-heavy exudate | Dressings 22 cm x 25 cm, 5 |
| 355  |  12208M  | Dressing-non-adherent with silicone | Dressings 5 cm x 7.5 cm, 10 |
| 356  |  12213T  | Dressing-gelling fibre | Dressings, non-woven, 1 cm x 45 cm, 5 |
| 357  |  12216Y  | Dressing-foam with silicone-heavy exudate | Dressings 16 cm x 20 cm, 5 |
| 358  |  12591Q  | Dressing with silver | Tulle dressings 10 cm x 10 cm, 10 |
| 359  |  12592R  | Bandage-compression | Bandage, two layer |
| 360  |  12593T  | Dressing-non-adherent absorbent | Dressings 10 cm x 20 cm, 10 |
| 361  |  12596Y  | Psyllium hydrophilic mucilloid | Oral powder (non-flavoured) 504 g |
| 362  |  12599D  | Dressing-non-adherent absorbent | Dressings 20 cm x 40 cm, 10 |
| 363  |  12600E  | Dressing-non-adherent absorbent | Dressings 10 cm x 10 cm, 10 |
| 364  |  12629Q  | Dressing-hydroactive (debridement) | Dressings 5.5 cm, 10 |
| 365  |  12636C  | Dressing-hydroactive (debridement) | Dressings, cavity, 4 cm, 10 |
| 366  |  12637D  | Dressing-hydroactive (debridement) | Dressings 4 cm, 10 |
| 367  |  12651W  | Dressing-non-adherent with silicone | Dressings 7.5 cm x 10 cm, 5 |
| 368  |  12659G  | Dressing-hydrogel | Dressings 12.5 cm x 12.5 cm, 5 |
| 369  |  12660H  | Dressing-hydroactive (debridement) | Dressings 7.5 cm x 7.5 cm, 10 |
| 370  |  12760N  | Dressing-foam-heavy exudate | Dressings 10 cm x 10 cm, 5 |
| 371  |  12765W  | Dressing alginate with silver (cavity wound) | Dressings, medicated, 3 cm x 44 cm, 10 |
| 372  |  12772F  | Dressing alginate with silver (deep wound) | Dressings, medicated, 5 cm x 5 cm, 10 |
| 373  |  12774H  | Dressing-foam with silicone-light exudate | Dressings 5 cm x 12.5 cm, 5 |
| 374  |  12776K  | Dressing-foam-heavy exudate | Dressings 20 cm x 20 cm, 5 |
| 375  |  12777L  | Dressing-foam with silicone-moderate exudate | Dressings 4 cm x 5 cm, 10 |
| 376  |  12780P  | Dressing-foam with silicone-light exudate | Dressings 4 cm x 5 cm, 10 |
| 377  |  12782R  | Dressing-foam with silicone-moderate exudate | Dressings 5 cm x 12.5 cm, 5 |
| 378  |  12797M  | Dressing-foam-heavy exudate | Dressings 5 cm x 5 cm, 5 |
| 379  |  12799P  | Dressing-foam with silicone-moderate exudate | Dressings 10 cm x 10 cm, 5 |
| 380  |  12801R  | Dressing alginate with silver (deep wound) | Dressings, medicated, 10 cm x 10 cm, 10 |
| 381  |  12804X  | Dressing-foam with silicone-light exudate | Dressings 10 cm x 10 cm, 5 |
| 382  |  12824Y  | Dressing-non-adherent absorbent | Dressings 23 cm x 25 cm, 30 |
| 383  |  12825B  | Dressing-non-adherent absorbent | Dressings 10 cm x 23 cm, 50 |
| 384  |  12832J  | Dressing-non-adherent absorbent | Dressings 10 cm x 13 cm, 50 |
| 385  |  12833K  | Dressing-non-adherent absorbent | Dressings, hydroactive, 22.5 cm x 32.5 cm, 10 |
| 386  |  12834L  | Dressing-non-adherent absorbent | Dressings, hydroactive, 17.5 cm x 22.5 cm, 10 |
| 387  |  12837P  | Dressing-non-adherent absorbent | Dressings, hydroactive, 12.5 cm x 12.5 cm, 10 |
| 388  |  13002H  | Dressing-contact layer lipidocolloid with sucrose octasulfate | Dressings 10 cm x 10 cm, 10 |
| 389  |  13003J  | Dressing-foam lipidocolloid with sucrose octasulfate-moderate exudate | Dressings 15 cm x 20 cm, 10 |
| 390  |  13004K  | Dressing-foam lipidocolloid with sucrose octasulfate-moderate exudate | Dressings 12 cm x 19 cm, 10 |
| 391  |  13005L  | Bandage-compression | Bandage, two layer, 18 cm to 25 cm |
| 392  |  13006M  | Bandage-compression | Bandage, two layer, 18 cm to 25 cm |
| 393  |  13007N  | Dressing-foam lipidocolloid with silicone-heavy exudate | Dressings 10 cm x 10 cm, 10 |
| 394  |  13008P  | Dressing-foam lipidocolloid with sucrose octasulfate-moderate exudate | Dressings 10 cm x 10 cm, 10 |
| 395  |  13009Q  | Dressing-gelling fibre lipidocolloid | Dressings 15 cm x 20 cm, 10 |
| 396  |  13010R  | Bandage-compression | Bandage, two layer, 25 cm to 32 cm |
| 397  |  13011T  | Dressing-contact layer lipidocolloid with sucrose octasulfate | Dressings 15 cm x 20 cm, 10 |
| 398  |  13012W  | Dressing poly-absorbent fibre lipidocolloid with sucrose octasulfate-moderate exudate | Dressings 15 cm x 20 cm, 10 |
| 399  |  13013X  | Dressing poly-absorbent fibre lipidocolloid with sucrose octasulfate-heavy exudate | Dressings 8 cm x 8 cm, 10 |
| 400  |  13014Y  | Dressing poly-absorbent fibre lipidocolloid with sucrose octasulfate-heavy exudate | Dressings 10 cm x 10 cm, 10 |
| 401  |  13015B  | Dressing-gelling fibre lipidocolloid | Dressings 10 cm x 10 cm, 10 |
| 402  |  13016C  | Bandage-compression | Bandage, two layer, 25 cm to 32 cm |
| 403  |  13017D  | Dressing-foam lipidocolloid with sucrose octasulfate-heavy exudate | Dressings 10 cm x 10 cm, 10 |
| 404  |  13018E  | Dressing poly-absorbent fibre lipidocolloid with sucrose octasulfate-heavy exudate | Dressings 15 cm x 20 cm, 5 |
| 405  |  13019F  | Dressing poly-absorbent fibre lipidocolloid with sucrose octasulfate-heavy exudate | Dressings 10 cm x 10 cm, 10 |
| 406  |  13021H  | Dressing-foam lipidocolloid with sucrose octasulfate-heavy exudate | Dressings 15 cm x 20 cm, 10 |
| 407  |  13022J  | Dressing-contact layer lipidocolloid | Dressings 10 cm x 10 cm, 10 |
| 408  |  13023K  | Dressing-foam lipidocolloid with sucrose octasulfate-heavy exudate | Dressings 8 cm x 8 cm, 10 |
| 409  |  13024L  | Dressing poly-absorbent fibre lipidocolloid with sucrose octasulfate-heavy exudate | Dressings 15 cm x 20 cm, 10 |
| 410  |  13025M  | Dressing poly-absorbent fibre lipidocolloid with sucrose octasulfate-moderate exudate | Dressings 10 cm x 10 cm, 10 |
| 411  |  13026N  | Dressing-lipidocolloid-moderate exudate | Dressings 10 cm x 12 cm, 16 |
| 412  |  13188D  | Bemotrizinol with diethylamino hydroxybenzoyl hexyl benzoate, homosalate, octocrylene and titanium dioxide | Lotion 1.8%-4%-8%-8%-2.5%, 125 mL |
| 413  |  13307J  | Zopiclone | Tablet 7.5 mg |
| 414  |  13331P  | Dressing-lipidocolloid-moderate exudate | Dressings 10 cm x 12 cm, 10 |
| 415  |  13758D  | Fluorouracil | Cream 40 mg per g (4%), 20 g |
| 416  |  14174B  | Calcium | Tablet 600 mg (as carbonate) |
| 417  |  14175C  | Calcium | Tablet 600 mg (as carbonate) |
| 418  |  14176D  | Calcium | Tablet, chewable, 500 mg (as carbonate) |
| 419  |  14180H  | Chloramphenicol | Eye drops 5 mg per mL, 10 mL |
| 420  |  14182K  | Thiamine | Tablet containing thiamine hydrochloride 100 mg |
| 421  |  14183L  | Alfuzosin hydrochloride | Tablet 10 mg |
| 422  |  14184M  | Dutasteride with tamsulosin | Capsule containing dutasteride 500 micrograms with tamsulosin hydrochloride 400 micrograms |
| 423  |  14185N  | Silodosin | Capsule 4 mg |
| 424  |  14191X  | Finasteride | Tablet 5 mg |
| 425  |  14192Y  | Silodosin | Capsule 8 mg |
| 426  |  14197F  | Risedronic acid | Tablet containing risedronate sodium 35 mg |
| 427  |  14198G  | Risedronic acid | Tablet (enteric coated) containing risedronate sodium 35 mg |
| 428  |  14199H  | Finasteride | Tablet 5 mg |
| 429  |  14200J  | Tamsulosin hydrochloride | Tablet 400 micrograms (prolonged release) |
| 430  |  14209W  | Risedronic acid | Tablet containing risedronate sodium 5 mg |
| 431  |  14210X  | Dutasteride | Capsule 500 micrograms |
| 432  |  14217G  | Calcium | Tablet, chewable, 500 mg (as carbonate) |
| 433  |  14567Q  | Bisacodyl | Suppositories 10 mg, 10 |
| 434  |  14572Y  | Bisacodyl | Suppositories 10 mg, 12 |

Endnotes

Endnote 1—About the endnotes

The endnotes provide information about this compilation and the compiled law.

The following endnotes are included in every compilation:

Endnote 1—About the endnotes

Endnote 2—Abbreviation key

Endnote 3—Legislation history

Endnote 4—Amendment history

**Abbreviation key—Endnote 2**

The abbreviation key sets out abbreviations that may be used in the endnotes.

**Legislation history and amendment history—Endnotes 3 and 4**

Amending laws are annotated in the legislation history and amendment history.

The legislation history in endnote 3 provides information about each law that has amended (or will amend) the compiled law. The information includes commencement details for amending laws and details of any application, saving or transitional provisions that are not included in this compilation.

The amendment history in endnote 4 provides information about amendments at the provision (generally section or equivalent) level. It also includes information about any provision of the compiled law that has been repealed in accordance with a provision of the law.

**Editorial changes**

The *Legislation Act 2003* authorises First Parliamentary Counsel to make editorial and presentational changes to a compiled law in preparing a compilation of the law for registration. The changes must not change the effect of the law. Editorial changes take effect from the compilation registration date.

If the compilation includes editorial changes, the endnotes include a brief outline of the changes in general terms. Full details of any changes can be obtained from the Office of Parliamentary Counsel.

**Misdescribed amendments**

A misdescribed amendment is an amendment that does not accurately describe how an amendment is to be made. If, despite the misdescription, the amendment can be given effect as intended, then the misdescribed amendment can be incorporated through an editorial change made under section 15V of the *Legislation Act 2003*.

If a misdescribed amendment cannot be given effect as intended, the amendment is not incorporated and “(md not incorp)” is added to the amendment history.

Endnote 2—Abbreviation key

|  |  |
| --- | --- |
| ad = added or inserted | o = order(s) |
| am = amended | Ord = Ordinance |
| amdt = amendment | orig = original |
| c = clause(s) | par = paragraph(s)/subparagraph(s) |
| C[x] = Compilation No. x | /sub‑subparagraph(s) |
| Ch = Chapter(s) | pres = present |
| def = definition(s) | prev = previous |
| Dict = Dictionary | (prev…) = previously |
| disallowed = disallowed by Parliament | Pt = Part(s) |
| Div = Division(s) | r = regulation(s)/rule(s) |
| ed = editorial change | reloc = relocated |
| exp = expires/expired or ceases/ceased to have | renum = renumbered |
| effect | rep = repealed |
| F = Federal Register of Legislation | rs = repealed and substituted |
| gaz = gazette | s = section(s)/subsection(s) |
| LA = *Legislation Act 2003* | Sch = Schedule(s) |
| LIA = *Legislative Instruments Act 2003* | Sdiv = Subdivision(s) |
| (md) = misdescribed amendment can be given | SLI = Select Legislative Instrument |
| effect | SR = Statutory Rules |
| (md not incorp) = misdescribed amendment | Sub‑Ch = Sub‑Chapter(s) |
| cannot be given effect | SubPt = Subpart(s) |
| mod = modified/modification | underlining = whole or part not |
| No. = Number(s) | commenced or to be commenced |

Endnote 3—Legislation history

| Name | Registration | Commencement | Application, saving and transitional provisions |
| --- | --- | --- | --- |
| 2013 No. R43 | 29 Nov 2013 (F2013L02009) | 30 Nov 2013 |  |
| 2015 No. R1/MRCC1 | 30 Mar 2015 (F2015L00376) | 1 Apr 2015 | s 3, s 4 |
| 2015 No. R45 | 24 Dec 2015 (F2015L02130) | Sch Part A: 25 Dec 2015 (s 2(1) item 2)Sch Part B: 1 Jan 2016 (s 2(1) item 3) | — |
| 2016 No. R49/MRCC49 | 6 Dec 2016 (F2016L01872) | 1 Jan 2017 | — |
| 2017 No. R14/MRCC14 | 21 June 2017 (F2017L00705) | 1 July 2017 | — |
| 2017 No. R7/MRCC7 | 14 Dec 2017 (F2017L01618) | 1 Jan 2018 | — |
| 2018 No. R34/MRCC34 | 22 June 2018 (F2018L00847) | Sch 1: 1 July 2018 (s 2) | — |
| 2019 No. R44/MRCC44 | 30 Oct 2019 (F2019L01387) | Sch 1: 31 Oct 2019 (s 2) | — |
| 2020 No. R7/MRCC7 | 7 Feb 2020 (F2020L00100) | Sch 1: 13 Jan 2020 (s 2)  | — |
| 2020 No. R13/MRCC13 | 17 Apr 2020 (F2020L00437) | Sch 1: 18 Apr 2020 (s 2) | — |
| 2020 No. R21/MRCC21 | 1 July 2020 (F2020L01026) | Sch 1: 1 Jul 2020 (s 2) | — |
| 2020 No. R43/MRCC43 | 23 Feb 2021 (F2021L00138) | Sch: 23 Feb 2021 (s 2) | — |
| Veterans’ Affairs Pharmaceutical Benefits Schemes Amendment (Continued Dispensing—Emergency Measures) Determination 2023 | 22 Dec 2023 (F2023L01754) | 21 Dec 2023 (s 2) | — |
| Veterans’ Entitlements (Repatriation Pharmaceutical Benefits Scheme) Amendment (Additional Community Supply Support Payment) Determination 2024 | 18 Nov 2024 (F2024L01444) | 10 Oct 2024 (s 2) | — |
| Veterans’ Affairs Pharmaceutical Benefits Schemes (Continued Dispensing—Emergency Measure) Amendment Determination 2025 | 24 Feb 2025 (F2025L00191) | Sch 1 (items 2, 3): 6.52 pm (A.C.T.) 4 Feb 2025 (s 2) | — |

Endnote 4—Amendment history

| Provision affected | How affected |
| --- | --- |
| s 1B  | rep LIA s 48D |
| **Part 1** |  |
| s 2  | am F2023L01754 |
| s 3  | am 2015 No. R1/MRCC1; F2015L02130; am F2017L01618; am F2018L00847; am F2019L01387; ed C8; am F2020L00437; am F2020L01026; am F2024L01444 |
| s 4  | rs. 2015 No. R1/MRCC1 |
| **Part 2** |  |
| s 7  | rs. F2017L01618 |
| s 11  | rs. F2017L01618 |
| s 11AA  | ad 2015 No. R1/MRCC1; am F2019L01387 |
| s 11A  | ad 2015 No. R1/MRCC1; am. F2017L01618; am F2019L01387 |
| Heading preceding s 11B  | rep 2015 No. R1/MRCC1 |
| s 11B  | rs 2015 No. R1/MRCC1; am F2019L01387; ed C8; am F2020L01026 |
| s 11C  | rep. 2015 No. R1/MRCC1; ad F2019L01387 |
| s 11D  | ad F2019L01387 |
| Heading preceding s 12  | rep F2015L02130 |
| **Part 3** |  |
| s 16 s 16AAA……………………….. | am 2015 No. R1/MRCC1; am. F2017L01618; am F2020L00437ad F2020L00437 |
| s 16AA  | ad. 2015 No. R1/MRCC1; am F2017L01618 |
| s 16A  | am. F2017L01618; am. F2020L00100; am F2023L01754; am F2025L00191 |
| s 16AB  | ad. 2015 No. R1/MRCC1 |
| s 21A  | ad F2015L02130; am F2020L01026; am F2024L01444 |
| **Part 4** |  |
| s 24A  | rep. 2015 No. R1/MRCC1 |
| s 24  | am 2015 No. R1/MRCC1 |
| s 24B  | rep. 2015 No. R1/MRCC1 |
| s 25  | rs. 2015 No. R1/MRCC1 |
| **Part 5** |  |
| s 26  | rs F2015L02130 |
| s 27  | rep F2015L02130 |
| s 28  | rep F2015L02130 |
| s 29  | rep F2015L02130 |
| s 30  | am F2015L02130 |
| s 32A  | ad F2024L01444 |
| **Part 5A** |  |
| s 37  | rs. 2015 No. R1/MRCC1 |
| **Part 5B**s 40A  | am F2021L00138 |
| **Part 6** |  |
| s 41  | rs. F2017L01618 |
| s 42  | rep. F2017L01618 |
| s 43  | rs 2015 No. R1/MRCC1; am F2017L01618; am F2019L01387 |
| s 45  | ad. 2015 No. R1/MRCC1; am. F2017L01618 |
| s 45A  | ad. 2015 No. R1/MRCC1; am F2017L01618 |
| s 45B  | ad F2019L01387; am F2020L01026 |
| s 47  | am. 2015 No. R1/MRCC1 |
| **Schedule 1** |  |
| Schedule 1  | rs F2015L02130; rs F2016L01872; rs F2017L00705; rs F2017L01618; rs F2018L00847; am F2020L01026; am F2024L01444 |
| **Schedule 2** |  |
| Schedule 2……………………… | ad F2020L00100; am F2020L01026; am F2023L01754; rs F2025L00191 |